Author: "Bacci, S" / Publication Year Range: Last 10 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Bacci, S"' showing total 126 results

Start Over Author "Bacci, S" Publication Year Range Last 10 years

126 results on '"Bacci, S"'

1. Assessment of the University Reputation Through the Analysis of the Student Mobility

Author: Bacci, S. and Bertaccini, B.
Published: 2021

2. Gundelia tournefortii L. (Akkoub): a review of a valuable wild vegetable from Eastern Mediterranean.

Author: Hani, N., Abulaila, K., Howes, M.-J. R., Mattana, E., Bacci, S., Sleem, K., Sarkis, L., Eddine, N. Saed, Baydoun, S., Apostolides, N. Arnold, and Ulian, T.
Abstract: Gundelia tournefortii L. (Asteraceae) is an artichoke-like wild edible vegetable that grows in the semi-arid climate of the East Mediterranean. Due to its high cultural and economic values for culinary and therapeutic uses, this plant is exposed to overharvesting driven by household consumption and trade, threatening the survival of natural populations. Some limited data on the nutrient composition of G. tournefortii exists indicating presence of folic acid and several essential amino acids. Research on seed germination reports that mechanical scarification, gibberellic acid, and cold stratification are all effective treatments for seed dormancy breaking and therefore to propagate plants from seed. Successful vegetative propagation from the plant meristems is also available. However, despite some exceptions, the species is still not widely cultivated due to its thorny habit and complex seed germination requirements, and the ability to ensure seed germination under natural field conditions remains to be addressed. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

3. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus

Author: Mantovani, A, Morieri, M, Aldigeri, R, Palmisano, L, Masulli, M, Bonomo, K, Baroni, M, Cossu, E, Cimini, F, Cavallo, G, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Pollis, R, Cas, A, de Kreutzenberg, S, Targher, G, Mantovani, Alessandro, Morieri, Mario Luca, Aldigeri, Raffaella, Palmisano, Luisa, Masulli, Maria, Bonomo, Katia, Baroni, Marco Giorgio, Cossu, Efisio, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, Targher, Giovanni, Mantovani, A, Morieri, M, Aldigeri, R, Palmisano, L, Masulli, M, Bonomo, K, Baroni, M, Cossu, E, Cimini, F, Cavallo, G, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Pollis, R, Cas, A, de Kreutzenberg, S, Targher, G, Mantovani, Alessandro, Morieri, Mario Luca, Aldigeri, Raffaella, Palmisano, Luisa, Masulli, Maria, Bonomo, Katia, Baroni, Marco Giorgio, Cossu, Efisio, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, and Targher, Giovanni
Abstract: Aim: We examined whether metabolic dysfunction-associated steatotic liver disease (MASLD) with or without significant fibrosis (assessed by validated non-invasive biomarkers) was associated with an increased risk of prevalent chronic kidney disease (CKD) or diabetic retinopathy in people with type 1 diabetes mellitus (T1DM). Methods: We performed a retrospective multicenter cross-sectional study involving 1,409 adult outpatients with T1DM, in whom hepatic steatosis index (HSI) and fibrosis (FIB)-4 index were calculated for non-invasively detecting hepatic steatosis (defined by HSI > 36), with or without coexisting significant fibrosis (FIB-4 index ≥ 1.3 or < 1.3). CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or urine albumin/creatinine ratio ≥ 3.0 mg/mmol. The presence of diabetic retinopathy was also recorded in all participants. Results: Patients with MASLD and significant fibrosis (n = 93) had a remarkably higher prevalence of CKD and diabetic retinopathy than their counterparts with MASLD without fibrosis (n = 578) and those without steatosis (n = 738). After adjustment for sex, diabetes duration, hemoglobin A1c, hypertension, and use of antihypertensive or lipid-lowering medications, patients with SLD and significant fibrosis had a higher risk of prevalent CKD (adjusted-odds ratio 1.76, 95 % confidence interval 1.05–2.96) than those without steatosis. Patients with MASLD without fibrosis had a higher risk of prevalent retinopathy (adjusted-odds ratio 1.49, 95 % CI 1.13–1.46) than those without steatosis. Conclusion: This is the largest cross-sectional study showing that MASLD with and without coexisting significant fibrosis was associated, independently of potential confounders, with an increased risk of prevalent CKD and retinopathy in adults with T1DM.
Published: 2024

4. Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus

Author: Csermely, A, Mantovani, A, Morieri, M, Palmisano, L, Masulli, M, Cossu, E, Baroni, M, Bonomo, K, Cimini, F, Cavallo, G, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Pollis, R, Aldigeri, R, Cas, A, de Kreutzenberg, S, Targher, G, Csermely, Alessandro, Mantovani, Alessandro, Morieri, Mario Luca, Palmisano, Luisa, Masulli, Maria, Cossu, Efisio, Baroni, Marco Giorgio, Bonomo, Katia, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Aldigeri, Raffaella, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, Targher, Giovanni, Csermely, A, Mantovani, A, Morieri, M, Palmisano, L, Masulli, M, Cossu, E, Baroni, M, Bonomo, K, Cimini, F, Cavallo, G, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Pollis, R, Aldigeri, R, Cas, A, de Kreutzenberg, S, Targher, G, Csermely, Alessandro, Mantovani, Alessandro, Morieri, Mario Luca, Palmisano, Luisa, Masulli, Maria, Cossu, Efisio, Baroni, Marco Giorgio, Bonomo, Katia, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Aldigeri, Raffaella, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, and Targher, Giovanni
Abstract: Aim: We examined whether different insulin administration modalities, i.e., multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII by insulin pumps), are differently associated with the risk of having metabolic dysfunction-associated fatty liver disease (MAFLD), with or without coexisting significant liver fibrosis (assessed by validated non-invasive biomarkers), in adults with type 1 diabetes mellitus (T1DM). Methods: We conducted a retrospective, multicenter, cross-sectional study involving 1,417 adult individuals with established T1DM treated with MDI or CSII. We calculated hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting MAFLD (defined by HSI >36), with or without coexisting significant fibrosis (defined by FIB-4 index ≥ 1.3 or <1.3, respectively). Results: Compared to the MDI group (n = 1,161), insulin-pump users (n = 256; 18.1%) were more likely to be younger (mean age: 40 vs. 48 years, P < 0.001), had better glycemic control (mean hemoglobin A1c: 7.7% vs. 7.9%, P = 0.025) and a markedly lower prevalence of MAFLD with coexisting significant fibrosis (2.7% vs. 8.1%, P = 0.010), but a comparable prevalence of MAFLD without fibrosis. In multinomial logistic regression analysis, CSII therapy was associated with a ∼70%-lower risk of MAFLD with significant fibrosis (unadjusted odds ratio 0.32, 95% confidence interval 0.14–0.70; P = 0.004), but this association was no longer significant after adjustment for age, hemoglobin A1c and other potential confounders. Conclusion: The lower prevalence of MAFLD with coexisting significant fibrosis we observed in adults with T1DM using CSII therapy, compared to those using MDI therapy, is primarily mediated by inter-group differences in age.
Published: 2023

5. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus

Author: Mantovani, A, Morieri, M, Palmisano, L, Masulli, M, Cossu, E, Baroni, M, Bonomo, K, Cimini, F, Cavallo, G, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Pollis, R, Aldigeri, R, Cas, A, de Kreutzenberg, S, Targher, G, Mantovani, Alessandro, Morieri, Mario Luca, Palmisano, Luisa, Masulli, Maria, Cossu, Efisio, Baroni, Marco Giorgio, Bonomo, Katia, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Aldigeri, Raffaella, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, Targher, Giovanni, Mantovani, A, Morieri, M, Palmisano, L, Masulli, M, Cossu, E, Baroni, M, Bonomo, K, Cimini, F, Cavallo, G, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Pollis, R, Aldigeri, R, Cas, A, de Kreutzenberg, S, Targher, G, Mantovani, Alessandro, Morieri, Mario Luca, Palmisano, Luisa, Masulli, Maria, Cossu, Efisio, Baroni, Marco Giorgio, Bonomo, Katia, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Aldigeri, Raffaella, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, and Targher, Giovanni
Abstract: Background: We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (CVD) in people with type 1 diabetes mellitus (T1DM). Methods: We conducted a retrospective, multicenter, cross-sectional study involving 1,254 adults with established T1DM without pre-existing CVD. We used the hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting hepatic steatosis (defined as HSI > 36), with or without coexisting significant fibrosis (defined as FIB-4 index ≥ 1.3 or < 1.3). We calculated the Steno type 1 risk engine and the atherosclerotic CVD (ASCVD) risk score to estimate the 10-year risk of developing a first fatal or nonfatal CVD event. Results: Using the Steno type 1 risk engine, a significantly greater proportion of patients with hepatic steatosis and significant fibrosis (n = 91) had a high 10-year estimated CVD risk compared to those with hepatic steatosis alone (n = 509) or without steatosis (n = 654) (75.8% vs. 23.2% vs. 24.9%, p < 0.001). After adjustment for sex, BMI, diabetes duration, hemoglobin A1c, chronic kidney disease, and lipid-lowering medication use, patients with hepatic steatosis and significant fibrosis had an increased 10-year estimated risk of developing a first fatal or nonfatal CVD event (adjusted-odds ratio 11.4, 95% confidence interval 3.54–36.9) than those without steatosis. We observed almost identical results using the ASCVD risk calculator. Conclusions: The 10-year estimated CVD risk is remarkably greater in T1DM adults with hepatic steatosis and significant fibrosis than in their counterparts with hepatic steatosis alone or without steatosis.
Published: 2023

6. Sex differences in cardiovascular disease and cardiovascular risk estimation in patients with type 1 diabetes

Author: Dei Cas, A, Aldigeri, R, Mantovani, A, Masulli, M, Palmisano, L, Cavalot, F, Bonomo, K, Baroni, M, Cossu, E, Cavallo, G, Cimini, F, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Morieri, M, Pollis, R, Targher, G, Vigili de Kreutzenberg, S, Dei Cas, Alessandra, Aldigeri, Raffaella, Mantovani, Alessandro, Masulli, Maria, Palmisano, Luisa, Cavalot, Franco, Bonomo, Katia, Baroni, Marco Giorgio, Cossu, Efisio, Cavallo, Gisella, Cimini, Flavia Agata, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Morieri, Mario Luca, Pollis, Riccardo Maria, Targher, Giovanni, Vigili de Kreutzenberg, Saula, Dei Cas, A, Aldigeri, R, Mantovani, A, Masulli, M, Palmisano, L, Cavalot, F, Bonomo, K, Baroni, M, Cossu, E, Cavallo, G, Cimini, F, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Morieri, M, Pollis, R, Targher, G, Vigili de Kreutzenberg, S, Dei Cas, Alessandra, Aldigeri, Raffaella, Mantovani, Alessandro, Masulli, Maria, Palmisano, Luisa, Cavalot, Franco, Bonomo, Katia, Baroni, Marco Giorgio, Cossu, Efisio, Cavallo, Gisella, Cimini, Flavia Agata, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Morieri, Mario Luca, Pollis, Riccardo Maria, Targher, Giovanni, and Vigili de Kreutzenberg, Saula
Abstract: Aims: Patients with type 1 diabetes (T1D) have higher cardiovascular disease (CVD) risk compared to the general population. This observational study aims to evaluate sex-related differences in CVD prevalence and CVD risk estimates in a large cohort of T1D adults. Materials and methods: We conducted a multicenter, cross-sectional study involving 2,041 T1D patients (mean age 46 years; 44.9% women). In patients without pre-existing CVD (primary prevention), we calculated the Steno type 1 risk engine to estimate the 10-year risk of developing CVD events. Results: CVD prevalence (n=116) was higher in men than in women aged ≥55 years (19.2 vs 12.8%, p=0.036), but comparable between the two sexes in those aged <55 years (p=0.91). In patients without pre-existing CVD (n=1,925), mean 10-year estimated CVD risk was 15.4±0.4% without any significant sex difference. However, stratifying this patient group by age, the 10-year estimated CVD risk was significantly higher in men than in women until age 55 years (p<0.001), but this risk equalized after this age. Carotid-artery plaque burden was significantly associated with age ≥55 years and with a medium and high 10-year estimated CVD risk, without any significant sex difference. Diabetic retinopathy and sensory-motor neuropathy were also associated with higher 10-year CVD risk and female sex. Conclusions: Both men and women with T1D are at high CVD risk. The 10-year estimated CVD risk was higher in men aged <55 years than in women of similar age, but these sex differences disappeared at age ≥55 years, suggesting that female sex was no longer protective.
Published: 2023

7. Latent trait models for perceived risk assessment using a Covid-19 data survey.

Author: Bacci, S., Fabbricatore, R., and Iannario, Maria
Subjects: *ITEM response theory, *COVID-19, *LATENT class analysis (Statistics), *RISK assessment, *NUCLEAR weapons
Abstract: Aim of the contribution is analyzing potential events that may negatively impact individuals, assets, and/or the environment, and making judgments about the perceived personal and social riskiness of Covid-19 compared to other hazards belonging to health (AIDS, cancer, infarction), environmental (climate change), behavioral (serious car accidents), and technological (nuclear weapons) domains. The comparative risk analysis has been performed on a survey data collected during the first Italian Covid-19 lockdown. An item response theory model for polytomously scored items has been implemented for the analysis of the positioning of Covid-19 with respect to the other hazards in terms of perceived risk. Among the attributes determining the hazard's perceived risk, Covid-19 distinguishes for the knowledge of risks from the hazard, media attention, and fear caused by the hazard in the peers. Besides, through a latent regression analysis, the role of some individual characteristics on the perceived risk for Covid-19 has been examined. Our contribution allows us to disentangle among several aspects of hazards and describe the main factors affecting the perceived risk. It also contributes to determine if existing control measures are perceived as adequate and the interest for new media with related impact on a person's reaction. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

8. Incidence and severity of pertussis hospitalisations in infants aged less than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT sentinel pilot surveillance system, December 2015 to December 2018

Author: Merdrignac L, Aït El Belghiti F, Pandolfi E, Jané M, Murphy J, Fabiánová K, García Cenoz M, Flem E, Guillot S, Tozzi AE, Carmona G, Habington A, Zavadilová J, Navasués A, Bøås H, Lévy-Brühl D, Ferretti B, Miguel Lanaspa Pérez, O'Sullivan N, Krížová P, Fernandino L, Bekkevold T, Hanslik T, Munoz-Almagro C, Bacci S, Spiteri G, Valenciano M, Moren A, PERTINENT Group, and PERTINENT group
Subjects: pertussis, active surveillance, hospital surveillance, pertussis incidence
Abstract: IntroductionPERTINENT is a pilot active surveillance system of infants hospitalised with pertussis in six European Union/European Economic Area countries (37 hospitals, seven sites).AimThis observational study aimed to estimate annual pertussis incidence per site from 2016 to 2018 and respective trends between 2017 and 2018. Pertussis cases were described, including their severity.MethodsWe developed a generic protocol and laboratory guidelines to harmonise practices across sites. Cases were hospitalised infants testing positive for Bordetella pertussis by PCR or culture. Sites collected demographic, clinical, laboratory data, vaccination status, and risk/protective factors. We estimated sites' annual incidences by dividing case numbers by the catchment populations.ResultsFrom December 2015 to December 2018, we identified 469 cases (247 males; 53%). The median age, birthweight and gestational age were 2.5 months (range: 0-11.6; interquartile range (IQR): 2.5), 3,280 g (range: 700-4,925; IQR: 720) and 39 weeks (range: 25-42; IQR: 2), respectively. Thirty cases (6%) had atypical presentation either with cough or cyanosis only or with absence of pertussis-like symptoms. Of 330 cases with information, 83 (25%) were admitted to intensive care units including five deceased infants too young to be vaccinated. Incidence rate ratios between 2018 and 2017 were 1.43 in Czech Republic (p = 0.468), 0.25 in Catalonia (p = 0.002), 0.71 in France (p = 0.034), 0.14 in Ireland (p = 0.002), 0.63 in Italy (p = 0.053), 0.21 in Navarra (p = 0.148) and zero in Norway.ConclusionsIncidence appeared to decrease between 2017 and 2018 in all but one site. Enhanced surveillance of hospitalised pertussis in Europe is essential to monitor pertussis epidemiology and disease burden.
Published: 2021

9. Latent trait models for perceived risk assessment using a Covid-19 data survey

Author: Bacci, S., primary, Fabbricatore, R., additional, and Iannario, Maria, additional
Published: 2021
Full Text: View/download PDF

10. Savoirs, entre éthos et pathos. Le cas de Roberto Saviano

Author: Bacci, S. (Simone), Heiden, L. (editor), and Tarrade, L. (editor)
Subjects: Sciences de l'Homme et Société/Linguistique
Abstract: Dans cet article nous mobiliserons la notion d’éthos discursif dans le cadre d’une analyse des stratégies syntactico-énonciatives mises en place par Roberto Saviano, journaliste expert de mafias, lorsqu’il prend la parole dans la presse et dans les réseaux sociaux. Nous voulons montrer comment Saviano transmet ses connaissances du milieux mafieux en adressant sa force persuasive en deux directions : vers soi, pour construire son image (l’éthos) et vers l’auditoire, pour susciter son émotion (le pathos).
Published: 2022
Full Text: View/download PDF

11. Increased expression of iNOS by Langerhans cells in hanging marks

Author: Focardi, M., primary, Bugelli, V., additional, Venturini, M., additional, Bianchi, I., additional, Defraia, B., additional, Pinchi, V., additional, and Bacci, S., additional
Published: 2020
Full Text: View/download PDF

12. Assessment of the University Reputation Through the Analysis of the Student Mobility

Author: Bacci, S., primary and Bertaccini, B., additional
Published: 2020
Full Text: View/download PDF

13. Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study

Author: Vitale, M, Masulli, M, Rivellese, A, Bonora, E, Cappellini, F, Nicolucci, A, Squatrito, S, Antenucci, D, Barrea, A, Bianchi, C, Bianchini, F, Fontana, L, Fornengo, P, Giorgino, F, Gnasso, A, Mannucci, E, Mazzotti, A, Nappo, R, Palena, A, Pata, P, Perriello, G, Potenziani, S, Radin, R, Ricci, L, Romeo, F, Santini, C, Scarponi, M, Serra, R, Timi, A, Turco, A, Vedovato, M, Zavaroni, D, Grioni, S, Riccardi, G, Vaccaro, O, Cocozza, S, Auciello, S, Cigolini, M, Pichiri, I, Brangani, C, Tomasetto, E, Sinagra, T, Longhitano, S, Tropea, V, Ballardini, G, Babini, A, Ripani, R, Gregori, G, Dolci, M, Bruselli, L, Salutini, I, Mori, M, Baccetti, F, Lapolla, A, Sartore, G, Burlina, S, Chilelli, N, Buzzetti, R, Venditti, C, Carlone, A, Galluzzo, A, Giordano, C, Torregrossa, V, Corsi, L, Cuneo, G, Corsi, S, Tizio, B, Galluzzo, G, Citro, G, Natale, M, Salvatore, V, Di Cianni, G, Lacaria, E, Russo, L, Iannarelli, R, De Gregorio, A, Sciarretta, F, D'Andrea, S, Montani, V, Cannarsa, E, Dolcetti, K, Cordera, R, Bonabello, L, Mazzucchelli, C, Giorda, C, Bonetto, C, Baldassarre, M, Iovine, C, Ciano, O, Dall'Aglio, E, Mancastroppa, G, Grimaldi, F, Tonutti, L, Boemi, M, D'Angelo, F, Leotta, S, Lauro, D, Rinaldi, M, Cignarelli, M, La Macchia, O, Fariello, S, Tomasi, F, Zamboni, C, Dozio, N, Trevisan, R, Scaranna, C, Del Prato, S, Miccoli, R, Garofolo, M, Pugliese, G, Salvi, L, Rangel, G, Anichini, R, Tedeschi, A, Corsini, E, Cucinotta, D, Di Benedetto, A, Giunta, L, Ruffo, M, Bossi, A, Carpinter, R, Dotta, F, Ceccarelli, E, Bartolo, P, Caselli, C, Luberto, A, Calbucci, G, Consoli, A, Ginestra, F, Calabrese, M, Zogheri, A, Laviola, L, Ippolito, C, Tarantino, L, Avogaro, A, Carallo, C, Scicchitano, C, Livraga, S, Perin, P, Forrnengo, P, Prinzis, T, De Cosmo, S, Bacci, S, Lamanna, C, Lettina, G, Aiello, A, Lalli, C, Franzetti, I, Petrachi, F, Asprino, V, Capra, C, Forte, E, Reggiani, G, Forlani, G, Montesi, L, Mazzella, N, Piatti, P, Monti, L, Stuccillo, M, Auletta, P, Petraroli, E, Capobianco, G, Romano, G, Cutolo, M, De Simone, G, Caiazzo, G, Nunziata, P, Sorrentino, S, Amelia, U, Calatola, P, Capuano, G, Vitale M., Masulli M., Rivellese A. A., Bonora E., Cappellini F., Nicolucci A., Squatrito S., Antenucci D., Barrea A., Bianchi C., Bianchini F., Fontana L., Fornengo P., Giorgino F., Gnasso A., Mannucci E., Mazzotti A., Nappo R., Palena A. P., Pata P., Perriello G., Potenziani S., Radin R., Ricci L., Romeo F., Santini C., Scarponi M., Serra R., Timi A., Turco A. A., Vedovato M., Zavaroni D., Grioni S., Riccardi G., Vaccaro O., Cocozza S., Auciello S., Cigolini M., Pichiri I., Brangani C., Tomasetto E., Sinagra T., Longhitano S., Tropea V., Ballardini G., Babini A. C., Ripani R., Gregori G., Dolci M., Bruselli L., Salutini I., Mori M., Baccetti F., Lapolla A., Sartore G., Burlina S., Chilelli N. C., Buzzetti R., Venditti C., Carlone A., Galluzzo A., Giordano C., Torregrossa V., Corsi L., Cuneo G., Corsi S., Tizio B., Galluzzo G., Citro G., Natale M., Salvatore V., Di Cianni G., Lacaria E., Russo L., Iannarelli R., De Gregorio A., Sciarretta F., D'Andrea S., Montani V., Cannarsa E., Dolcetti K., Cordera R., Bonabello L. A., Mazzucchelli C., Giorda C. B., Bonetto C., Baldassarre M. P. A., Iovine C., Ciano O., Dall'Aglio E., Mancastroppa G., Grimaldi F., Tonutti L., Boemi M., D'Angelo F., Leotta S., Lauro D., Rinaldi M. E., Cignarelli M., La Macchia O., Fariello S., Tomasi F., Zamboni C., Dozio N., Trevisan R., Scaranna C., Del Prato S., Miccoli R., Garofolo M., Pugliese G., Salvi L., Rangel G., Anichini R., Tedeschi A., Corsini E., Cucinotta D., Di Benedetto A., Giunta L., Ruffo M. C., Bossi A. C., Carpinter R., Dotta F., Ceccarelli E., Bartolo P. D., Caselli C., Luberto A., Calbucci G., Consoli A., Ginestra F., Calabrese M., Zogheri A., Laviola L., Ippolito C., Tarantino L., Avogaro A., Carallo C., Scicchitano C., Livraga S., Perin P. C., Forrnengo P., Prinzis T., De Cosmo S., Bacci S., Lamanna C., Lettina G., Aiello A., Lalli C., Franzetti I., Petrachi F., Asprino V., Capra C., Forte E., Reggiani G. M., Forlani G., Montesi L., Mazzella N., Piatti P. M., Monti L., Stuccillo M., Auletta P., Petraroli E., Capobianco G., Romano G., Cutolo M., De Simone G., Caiazzo G., Nunziata P., Sorrentino S., Amelia U., Calatola P., Capuano G., Vitale, M, Masulli, M, Rivellese, A, Bonora, E, Cappellini, F, Nicolucci, A, Squatrito, S, Antenucci, D, Barrea, A, Bianchi, C, Bianchini, F, Fontana, L, Fornengo, P, Giorgino, F, Gnasso, A, Mannucci, E, Mazzotti, A, Nappo, R, Palena, A, Pata, P, Perriello, G, Potenziani, S, Radin, R, Ricci, L, Romeo, F, Santini, C, Scarponi, M, Serra, R, Timi, A, Turco, A, Vedovato, M, Zavaroni, D, Grioni, S, Riccardi, G, Vaccaro, O, Cocozza, S, Auciello, S, Cigolini, M, Pichiri, I, Brangani, C, Tomasetto, E, Sinagra, T, Longhitano, S, Tropea, V, Ballardini, G, Babini, A, Ripani, R, Gregori, G, Dolci, M, Bruselli, L, Salutini, I, Mori, M, Baccetti, F, Lapolla, A, Sartore, G, Burlina, S, Chilelli, N, Buzzetti, R, Venditti, C, Carlone, A, Galluzzo, A, Giordano, C, Torregrossa, V, Corsi, L, Cuneo, G, Corsi, S, Tizio, B, Galluzzo, G, Citro, G, Natale, M, Salvatore, V, Di Cianni, G, Lacaria, E, Russo, L, Iannarelli, R, De Gregorio, A, Sciarretta, F, D'Andrea, S, Montani, V, Cannarsa, E, Dolcetti, K, Cordera, R, Bonabello, L, Mazzucchelli, C, Giorda, C, Bonetto, C, Baldassarre, M, Iovine, C, Ciano, O, Dall'Aglio, E, Mancastroppa, G, Grimaldi, F, Tonutti, L, Boemi, M, D'Angelo, F, Leotta, S, Lauro, D, Rinaldi, M, Cignarelli, M, La Macchia, O, Fariello, S, Tomasi, F, Zamboni, C, Dozio, N, Trevisan, R, Scaranna, C, Del Prato, S, Miccoli, R, Garofolo, M, Pugliese, G, Salvi, L, Rangel, G, Anichini, R, Tedeschi, A, Corsini, E, Cucinotta, D, Di Benedetto, A, Giunta, L, Ruffo, M, Bossi, A, Carpinter, R, Dotta, F, Ceccarelli, E, Bartolo, P, Caselli, C, Luberto, A, Calbucci, G, Consoli, A, Ginestra, F, Calabrese, M, Zogheri, A, Laviola, L, Ippolito, C, Tarantino, L, Avogaro, A, Carallo, C, Scicchitano, C, Livraga, S, Perin, P, Forrnengo, P, Prinzis, T, De Cosmo, S, Bacci, S, Lamanna, C, Lettina, G, Aiello, A, Lalli, C, Franzetti, I, Petrachi, F, Asprino, V, Capra, C, Forte, E, Reggiani, G, Forlani, G, Montesi, L, Mazzella, N, Piatti, P, Monti, L, Stuccillo, M, Auletta, P, Petraroli, E, Capobianco, G, Romano, G, Cutolo, M, De Simone, G, Caiazzo, G, Nunziata, P, Sorrentino, S, Amelia, U, Calatola, P, Capuano, G, Vitale M., Masulli M., Rivellese A. A., Bonora E., Cappellini F., Nicolucci A., Squatrito S., Antenucci D., Barrea A., Bianchi C., Bianchini F., Fontana L., Fornengo P., Giorgino F., Gnasso A., Mannucci E., Mazzotti A., Nappo R., Palena A. P., Pata P., Perriello G., Potenziani S., Radin R., Ricci L., Romeo F., Santini C., Scarponi M., Serra R., Timi A., Turco A. A., Vedovato M., Zavaroni D., Grioni S., Riccardi G., Vaccaro O., Cocozza S., Auciello S., Cigolini M., Pichiri I., Brangani C., Tomasetto E., Sinagra T., Longhitano S., Tropea V., Ballardini G., Babini A. C., Ripani R., Gregori G., Dolci M., Bruselli L., Salutini I., Mori M., Baccetti F., Lapolla A., Sartore G., Burlina S., Chilelli N. C., Buzzetti R., Venditti C., Carlone A., Galluzzo A., Giordano C., Torregrossa V., Corsi L., Cuneo G., Corsi S., Tizio B., Galluzzo G., Citro G., Natale M., Salvatore V., Di Cianni G., Lacaria E., Russo L., Iannarelli R., De Gregorio A., Sciarretta F., D'Andrea S., Montani V., Cannarsa E., Dolcetti K., Cordera R., Bonabello L. A., Mazzucchelli C., Giorda C. B., Bonetto C., Baldassarre M. P. A., Iovine C., Ciano O., Dall'Aglio E., Mancastroppa G., Grimaldi F., Tonutti L., Boemi M., D'Angelo F., Leotta S., Lauro D., Rinaldi M. E., Cignarelli M., La Macchia O., Fariello S., Tomasi F., Zamboni C., Dozio N., Trevisan R., Scaranna C., Del Prato S., Miccoli R., Garofolo M., Pugliese G., Salvi L., Rangel G., Anichini R., Tedeschi A., Corsini E., Cucinotta D., Di Benedetto A., Giunta L., Ruffo M. C., Bossi A. C., Carpinter R., Dotta F., Ceccarelli E., Bartolo P. D., Caselli C., Luberto A., Calbucci G., Consoli A., Ginestra F., Calabrese M., Zogheri A., Laviola L., Ippolito C., Tarantino L., Avogaro A., Carallo C., Scicchitano C., Livraga S., Perin P. C., Forrnengo P., Prinzis T., De Cosmo S., Bacci S., Lamanna C., Lettina G., Aiello A., Lalli C., Franzetti I., Petrachi F., Asprino V., Capra C., Forte E., Reggiani G. M., Forlani G., Montesi L., Mazzella N., Piatti P. M., Monti L., Stuccillo M., Auletta P., Petraroli E., Capobianco G., Romano G., Cutolo M., De Simone G., Caiazzo G., Nunziata P., Sorrentino S., Amelia U., Calatola P., and Capuano G.
Abstract: Purpose: Proper evaluation of polyphenols intake at the population level is a necessary step in order to establish possible associations with health outcomes. Available data are limited, and so far no study has been performed in people with diabetes. The aim of this work was to document the intake of polyphenols and their major food sources in a cohort of people with type 2 diabetes and in socio-demographic subgroups. Methods: We studied 2573 men and women aged 50–75 years. Among others, anthropometry was measured by standard protocol and dietary habits were investigated by food frequency questionnaire (EPIC). The intake of polyphenols was evaluated using US Department of Agriculture and Phenol-Explorer databases. Results: The mean total polyphenol intake was 683.3 ± 5.8 mg/day. Non-alcoholic beverages represented the main food source of dietary polyphenols and provided 35.5% of total polyphenol intake, followed by fruits (23.0%), alcoholic beverages (14.0%), vegetables (12.4%), cereal products and tubers (4.6%), legumes (3.7%) and oils (2.1%); chocolate, cakes and nuts are negligible sources of polyphenols in this cohort. The two most important polyphenol classes contributing to the total intake were flavonoids (47.5%) and phenolic acids (47.4%). Polyphenol intake increased with age and education level and decreased with BMI; furthermore, in the northern regions of Italy, the polyphenol intake was slightly, but significantly higher than in the central or southern regions. Conclusions: The study documents for the first time the intake of polyphenols and their main food sources in people with diabetes using validated and complete databases of the polyphenol content of food. Compared with published data, collected in people without diabetes, these results suggest a lower intake and a different pattern of intake in people with diabetes.
Published: 2018

14. Increased expression of iNOS by Langerhans cells in hanging marks.

Author: Focardi, M., Bugelli, V., Venturini, M., Bianchi, I., Defraia, B., Pinchi, V., and Bacci, S.
Subjects: LANGERHANS cells, CELL populations, CELLULAR control mechanisms, NITRIC oxide
Abstract: Recent studies show that Langerhans cell density increases in vital lesions and ligature marks when compared with post-mortal wounds. The enzyme, iNOS, has been established as a marker for estimating time of agony and serves in the regulation of dendritic cell behaviour. It is the aim of this paper, therefore, to evaluate the expression of this enzyme by Langerhans cells and the possible consequences that may be related to the production of nitric oxide by these cells in other types of lesions, including hanging furrows. The results show a greater expression of iNOS by Langerhans cells at the level of the hanging furrow when compared with other examined groups. Apart from an increase in the expression of iNOS, a large fraction of the mast cell population in the class II MHC molecules was observed in the hanging furrow. This corroborates that interactions between mast cells and dendritic cells are critical for the differentiation of these latter cellular types. Hence, the results suggest that iNOS plays a crucial role in the forensic practice of establishing the time interval in defining the vitality in hanging marks. [ABSTRACT FROM AUTHOR]
Published: 2022
Full Text: View/download PDF

15. Dishabituation to the mirror in domestic dogs: A pilot study

Author: Ogi, A., Naef, V., Bacci, S., and Gazzano, A.
Subjects: Mirror, Dishabituation, Dog, Habituation, Olfaction, Self-recognition
Published: 2020

16. Multilevel Model-Based Clustering: A New Proposal of Maximum-A-Posteriori Assignment

Author: Imaizumi, T, Okada, A, Miyamoto, S, Sakaori, F, Yamamoto, Y, Vichi, M, Bacci, S, Bartolucci, F, Pennoni, F, Imaizumi, T, Okada, A, Miyamoto, S, Sakaori, F, Yamamoto, Y, Vichi, M, Bacci, S, Bartolucci, F, and Pennoni, F
Abstract: We deal with the problem of latent variable prediction in the context of multilevel latent class models for categorical responses provided by individuals nested in groups. In particular, we propose a posterior assignment rule that jointly predicts the individual- and group-level latent variables. This proposal is alternative to the common maximum- a-posteriori rule, which is based on first predicting the latent variables at cluster level and, then, those at individual level. To illustrate the proposal, we show the results of two simulation studies and two applications on data related to the national and the international assessment of student skills.
Published: 2020

17. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Author: Vaccaro, O, Masulli, M, Nicolucci, A, Bonora, E, Del Prato, S, Maggioni, A, Rivellese, A, Squatrito, S, Giorda, C, Sesti, G, Mocarelli, P, Lucisano, G, Sacco, M, Signorini, S, Cappellini, F, Perriello, G, Babini, A, Lapolla, A, Gregori, G, Giordano, C, Corsi, L, Buzzetti, R, Clemente, G, Di Cianni, G, Iannarelli, R, Cordera, R, La Macchia, O, Zamboni, C, Scaranna, C, Boemi, M, Iovine, C, Lauro, D, Leotta, S, Dall'Aglio, E, Cannarsa, E, Tonutti, L, Pugliese, G, Bossi, A, Anichini, R, Dotta, F, Di Benedetto, A, Citro, G, Antenucci, D, Ricci, L, Giorgino, F, Santini, C, Gnasso, A, De Cosmo, S, Zavaroni, D, Vedovato, M, Consoli, A, Calabrese, M, di Bartolo, P, Fornengo, P, Riccardi, G, D'Angelo, F, Giansanti, R, Tanase, L, Lanari, L, Testa, I, Pancani, F, Ranchelli, A, Vagheggi, P, Scatona, A, Fontana, L, Laviola, L, Tarantino, L, Ippolito, C, Gigantelli, V, Manicone, M, Conte, E, Trevisan, R, Rota, R, Dodesini, A, Reggiani, G, Montesi, L, Mazzella, N, Forlani, G, Caselli, C, Di Luzio, R, Mazzotti, A, Aiello, A, Barrea, A, Musto, A, D'Amico, F, Sinagra, T, Longhitano, S, Trowpea, V, Sparti, M, Italia, S, Lisi, E, Grasso, G, Pezzino, V, Insalaco, F, Carallo, C, Scicchitano, C, De Franceschi, M, Calbucci, G, Ripani, R, Cuneo, G, Corsi, S, Romeo, F, Lesina, A, Comoglio, M, Bonetto, C, Robusto, A, Nada, E, Asprino, V, Cetraro, R, Impieri, M, Lucchese, G, Donnarumma, G, Tizio, B, Lenza, L, Paraggio, P, Tomasi, F, Dozio, N, Scalambra, E, Mannucci, E, Lamanna, C, Cignarelli, M, Macchia, O, Fariello, S, Sorrentino, M, Franzetti, I, Radin, R, Annunziata, F, Bonabello, L, Durante, A, Dolcino, M, Gallo, F, Mazzucchelli, C, Aleo, A, Melga, P, Briatore, L, Maggi, D, Storace, D, Cecoli, F, D'Ugo, E, Pupillo, M, Baldassarre, M, Salvati, F, Minnucci, A, De Luca, A, Zugaro, A, Santarelli, L, Bosco, A, Petrella, V, La Verghetta, G, D'Andrea, S, Giuliani, A, Polidoro, W, Sperandio, A, Sciarretta, F, Pezzella, A, Carlone, A, Potenziani, S, Venditti, C, Foffi, C, Carbone, S, Cipolloni, L, Moretti, C, Leto, G, Serra, R, Petrachi, F, Romano, I, Lacaria, E, Russo, L, Goretti, C, Sannino, C, Dolci, M, Bruselli, L, Mori, M, Baccetti, F, Del Freo, M, Cucinotta, D, Giunta, L, Ruffo, M, Cannizzaro, D, Pintaudi, B, Perrone, G, Pata, P, Ragonese, F, Lettina, G, Mancuso, T, Coppolino, A, Piatti, P, Monti, L, Stuccillo, M, Lucotti, P, Setola, M, Crippa, G, Loi, C, Oldani, M, Bottalico, M, Pellegata, B, Bonomo, M, Menicatti, L, Resi, V, Bertuzzi, F, Disoteo, E, Pizzi, G, Annuzzi, G, Capaldo, B, Nappo, R, Auciello, S, Turco, A, Costagliola, L, Corte, G, Vallefuoco, P, Nappi, F, Vitale, M, Cocozza, S, Ciano, O, Massimino, E, Garofalo, N, Avogaro, A, Guarneri, G, Fedele, D, Sartore, G, Chilelli, N, Burlina, S, Bonsembiante, B, Galluzzo, A, Torregrossa, V, Mancastroppa, G, Arsenio, L, Cioni, F, Caronna, S, Papi, M, Santeusanio, F, Calagreti, G, Timi, A, Tantucci, A, Marino, C, Ginestra, F, Di Biagio, R, Taraborelli, M, Miccoli, R, Bianchi, C, Garofolo, M, Politi, K, Penno, G, Livraga, S, Calzoni, F, Corsini, E, Tedeschi, A, Gagliano, M, Ippolito, G, Salutini, E, Cervellino, F, Natale, M, Salvatore, V, Zampino, A, Sinisi, R, Arcangeli, A, Zogheri, A, Guizzotti, S, Longo, R, Pellicano, F, Scolozzi, P, Termine, S, Luberto, A, Ballardini, G, Trojani, C, Mazzuca, P, Bruglia, M, Ciamei, M, Genghini, S, Zannoni, C, Rangel, G, Salvi, L, Zappaterreno, A, Cordone, S, Simonelli, P, Meggiorini, M, Frasheri, A, Di Pippo, C, Maglio, C, Mazzitelli, G, Rinaldi, M, Galli, A, Romano, M, D'Angelo, P, Suraci, C, Bacci, S, Palena, A, Genovese, S, Mancino, M, Rondinelli, M, Capone, F, Calabretto, E, Bulgheroni, M, Bucciarelli, L, Ceccarelli, E, Fondelli, C, Santacroce, C, Guarino, E, Nigi, L, Lalli, C, Di Vizia, G, Scarponi, M, Montani, V, Di Bernardino, P, Romagni, P, Dolcetti, K, Forte, E, Tamburo, L, Perin, P, Prinzis, T, Gruden, G, Bruno, G, Zucco, C, Perotta, M, Marena, S, Monsignore, S, Panero, F, Ponzi, F, Carpinteri, R, Casagrande, M, Coletti, M, Balini, A, Filopanti, M, Madaschi, S, Pulcina, A, Grimaldi, F, Venturini, G, Agus, S, Pagnutti, S, Guidotti, F, Cavarape, A, Cigolini, M, Pichiri, I, Brangani, C, Fainelli, G, Tomasetto, E, Zoppini, G, Galletti, A, Perrone, D, Capra, C, Bianchini, F, Ceseri, M, Di Nardo, B, Sasso, E, Bartolomei, B, Suliman, I, Fabbri, G, Romano, G, Maturo, N, Nunziata, G, Capobianco, G, De Simone, G, Villa, V, Rota, G, Pentangelo, C, Carbonara, O, Caiazzo, G, Cutolo, M, Sorrentino, T, Mastrilli, V, Amelia, U, Masi, S, Corigliano, G, Gaeta, I, Armentano, V, Calatola, P, Capuano, G, Angiulli, B, Auletta, P, Petraroli, E, Iodice, C, Agrusta, M, Vaccaro O., Masulli M., Nicolucci A., Bonora E., Del Prato S., Maggioni A. P., Rivellese A. A., Squatrito S., Giorda C. B., Sesti G., Mocarelli P., Lucisano G., Sacco M., Signorini S., Cappellini F., Perriello G., Babini A. C., Lapolla A., Gregori G., Giordano C., Corsi L., Buzzetti R., Clemente G., Di Cianni G., Iannarelli R., Cordera R., La Macchia O., Zamboni C., Scaranna C., Boemi M., Iovine C., Lauro D., Leotta S., Dall'Aglio E., Cannarsa E., Tonutti L., Pugliese G., Bossi A. C., Anichini R., Dotta F., Di Benedetto A., Citro G., Antenucci D., Ricci L., Giorgino F., Santini C., Gnasso A., De Cosmo S., Zavaroni D., Vedovato M., Consoli A., Calabrese M., di Bartolo P., Fornengo P., Riccardi G., D'Angelo F., Giansanti R., Tanase L., Lanari L., Testa I., Pancani F., Ranchelli A., Vagheggi P., Scatona A., Fontana L., Laviola L., Tarantino L., Ippolito C., Gigantelli V., Manicone M., Conte E., Trevisan R., Rota R., Dodesini A. R., Reggiani G. M., Montesi L., Mazzella N., Forlani G., Caselli C., Di Luzio R., Mazzotti A., Aiello A., Barrea A., Musto A., D'Amico F., Sinagra T., Longhitano S., Trowpea V., Sparti M., Italia S., Lisi E., Grasso G., Pezzino V., Insalaco F., Carallo C., Scicchitano C., De Franceschi M. S., Calbucci G., Ripani R., Cuneo G., Corsi S., Romeo F., Lesina A., Comoglio M., Bonetto C., Robusto A., Nada E., Asprino V., Cetraro R., Impieri M., Lucchese G., Donnarumma G., Tizio B., Lenza L., Paraggio P., Tomasi F., Dozio N., Scalambra E., Mannucci E., Lamanna C., Cignarelli M., Macchia O. L., Fariello S., Sorrentino M. R., Franzetti I., Radin R., Annunziata F., Bonabello L. A., Durante A., Dolcino M., Gallo F., Mazzucchelli C., Aleo A., Melga P., Briatore L., Maggi D., Storace D., Cecoli F., D'Ugo E., Pupillo M., Baldassarre M. P. A., Salvati F., Minnucci A., De Luca A., Zugaro A., Santarelli L., Bosco A., Petrella V., La Verghetta G. G., D'Andrea S., Giuliani A. E., Polidoro W. L., Sperandio A., Sciarretta F., Pezzella A., Carlone A., Potenziani S., Venditti C., Foffi C., Carbone S., Cipolloni L., Moretti C., Leto G., Serra R., Petrachi F., Romano I., Lacaria E., Russo L., Goretti C., Sannino C., Dolci M., Bruselli L., Mori M. L., Baccetti F., Del Freo M., Cucinotta D., Giunta L., Ruffo M. C., Cannizzaro D., Pintaudi B., Perrone G., Pata P., Ragonese F., Lettina G., Mancuso T., Coppolino A., Piatti P. M., Monti L., Stuccillo M., Lucotti P., Setola M., Crippa G. V., Loi C., Oldani M., Bottalico M. L., Pellegata B., Bonomo M., Menicatti L. S. M., Resi V., Bertuzzi F., Disoteo E. O., Pizzi G., Annuzzi G., Capaldo B., Nappo R., Auciello S. M., Turco A. A., Costagliola L., Corte G. D., Vallefuoco P., Nappi F., Vitale M., Cocozza S., Ciano O., Massimino E., Garofalo N., Avogaro A., Guarneri G., Fedele D., Sartore G., Chilelli N. C., Burlina S., Bonsembiante B., Galluzzo A., Torregrossa V., Mancastroppa G., Arsenio L., Cioni F., Caronna S., Papi M., Santeusanio F., Calagreti G., Timi A., Tantucci A., Marino C., Ginestra F., Di Biagio R., Taraborelli M., Miccoli R., Bianchi C., Garofolo M., Politi K. S., Penno G., Livraga S., Calzoni F., Mancastroppa G. L. F., Corsini E., Tedeschi A., Gagliano M. S., Ippolito G., Salutini E., Cervellino F., Natale M., Salvatore V., Zampino A., Sinisi R., Arcangeli A., Zogheri A., Guizzotti S., Longo R., Pellicano F., Scolozzi P., Termine S., Luberto A., Ballardini G., Trojani C., Mazzuca P., Bruglia M., Ciamei M., Genghini S., Zannoni C., Rangel G., Salvi L., Zappaterreno A., Cordone S., Simonelli P., Meggiorini M., Frasheri A., Di Pippo C., Maglio C., Mazzitelli G., Rinaldi M. E., Galli A., Romano M., D'Angelo P., Suraci C., Bacci S., Palena A. P., Genovese S., Mancino M., Rondinelli M., Capone F., Calabretto E., Bulgheroni M., Bucciarelli L., Ceccarelli E., Fondelli C., Santacroce C., Guarino E., Nigi L., Lalli C., Di Vizia G., Scarponi M., Montani V., Di Bernardino P., Romagni P., Dolcetti K., Forte E., Tamburo L., Perin P. C., Prinzis T., Gruden G., Bruno G., Zucco C., Perotta M., Marena S., Monsignore S., Panero F., Ponzi F., Carpinteri R., Casagrande M. L., Coletti M. F., Balini A., Filopanti M., Madaschi S., Pulcina A., Grimaldi F., Venturini G., Agus S., Pagnutti S., Guidotti F., Cavarape A., Cigolini M., Pichiri I., Brangani C., Fainelli G., Tomasetto E., Zoppini G., Galletti A., Perrone D., Capra C., Bianchini F., Ceseri M., Di Nardo B., Sasso E., Bartolomei B., Suliman I., Fabbri G., Romano G., Maturo N., Nunziata G., Capobianco G., De Simone G., Villa V., Rota G., Pentangelo C., Carbonara O., Caiazzo G., Cutolo M., Sorrentino T., Mastrilli V., Amelia U., Masi S., Corigliano G., Gaeta I., Armentano V., Calatola P., Capuano G., Angiulli B., Auletta P., Petraroli E., Iodice C. E., Agrusta M., Vaccaro, O, Masulli, M, Nicolucci, A, Bonora, E, Del Prato, S, Maggioni, A, Rivellese, A, Squatrito, S, Giorda, C, Sesti, G, Mocarelli, P, Lucisano, G, Sacco, M, Signorini, S, Cappellini, F, Perriello, G, Babini, A, Lapolla, A, Gregori, G, Giordano, C, Corsi, L, Buzzetti, R, Clemente, G, Di Cianni, G, Iannarelli, R, Cordera, R, La Macchia, O, Zamboni, C, Scaranna, C, Boemi, M, Iovine, C, Lauro, D, Leotta, S, Dall'Aglio, E, Cannarsa, E, Tonutti, L, Pugliese, G, Bossi, A, Anichini, R, Dotta, F, Di Benedetto, A, Citro, G, Antenucci, D, Ricci, L, Giorgino, F, Santini, C, Gnasso, A, De Cosmo, S, Zavaroni, D, Vedovato, M, Consoli, A, Calabrese, M, di Bartolo, P, Fornengo, P, Riccardi, G, D'Angelo, F, Giansanti, R, Tanase, L, Lanari, L, Testa, I, Pancani, F, Ranchelli, A, Vagheggi, P, Scatona, A, Fontana, L, Laviola, L, Tarantino, L, Ippolito, C, Gigantelli, V, Manicone, M, Conte, E, Trevisan, R, Rota, R, Dodesini, A, Reggiani, G, Montesi, L, Mazzella, N, Forlani, G, Caselli, C, Di Luzio, R, Mazzotti, A, Aiello, A, Barrea, A, Musto, A, D'Amico, F, Sinagra, T, Longhitano, S, Trowpea, V, Sparti, M, Italia, S, Lisi, E, Grasso, G, Pezzino, V, Insalaco, F, Carallo, C, Scicchitano, C, De Franceschi, M, Calbucci, G, Ripani, R, Cuneo, G, Corsi, S, Romeo, F, Lesina, A, Comoglio, M, Bonetto, C, Robusto, A, Nada, E, Asprino, V, Cetraro, R, Impieri, M, Lucchese, G, Donnarumma, G, Tizio, B, Lenza, L, Paraggio, P, Tomasi, F, Dozio, N, Scalambra, E, Mannucci, E, Lamanna, C, Cignarelli, M, Macchia, O, Fariello, S, Sorrentino, M, Franzetti, I, Radin, R, Annunziata, F, Bonabello, L, Durante, A, Dolcino, M, Gallo, F, Mazzucchelli, C, Aleo, A, Melga, P, Briatore, L, Maggi, D, Storace, D, Cecoli, F, D'Ugo, E, Pupillo, M, Baldassarre, M, Salvati, F, Minnucci, A, De Luca, A, Zugaro, A, Santarelli, L, Bosco, A, Petrella, V, La Verghetta, G, D'Andrea, S, Giuliani, A, Polidoro, W, Sperandio, A, Sciarretta, F, Pezzella, A, Carlone, A, Potenziani, S, Venditti, C, Foffi, C, Carbone, S, Cipolloni, L, Moretti, C, Leto, G, Serra, R, Petrachi, F, Romano, I, Lacaria, E, Russo, L, Goretti, C, Sannino, C, Dolci, M, Bruselli, L, Mori, M, Baccetti, F, Del Freo, M, Cucinotta, D, Giunta, L, Ruffo, M, Cannizzaro, D, Pintaudi, B, Perrone, G, Pata, P, Ragonese, F, Lettina, G, Mancuso, T, Coppolino, A, Piatti, P, Monti, L, Stuccillo, M, Lucotti, P, Setola, M, Crippa, G, Loi, C, Oldani, M, Bottalico, M, Pellegata, B, Bonomo, M, Menicatti, L, Resi, V, Bertuzzi, F, Disoteo, E, Pizzi, G, Annuzzi, G, Capaldo, B, Nappo, R, Auciello, S, Turco, A, Costagliola, L, Corte, G, Vallefuoco, P, Nappi, F, Vitale, M, Cocozza, S, Ciano, O, Massimino, E, Garofalo, N, Avogaro, A, Guarneri, G, Fedele, D, Sartore, G, Chilelli, N, Burlina, S, Bonsembiante, B, Galluzzo, A, Torregrossa, V, Mancastroppa, G, Arsenio, L, Cioni, F, Caronna, S, Papi, M, Santeusanio, F, Calagreti, G, Timi, A, Tantucci, A, Marino, C, Ginestra, F, Di Biagio, R, Taraborelli, M, Miccoli, R, Bianchi, C, Garofolo, M, Politi, K, Penno, G, Livraga, S, Calzoni, F, Corsini, E, Tedeschi, A, Gagliano, M, Ippolito, G, Salutini, E, Cervellino, F, Natale, M, Salvatore, V, Zampino, A, Sinisi, R, Arcangeli, A, Zogheri, A, Guizzotti, S, Longo, R, Pellicano, F, Scolozzi, P, Termine, S, Luberto, A, Ballardini, G, Trojani, C, Mazzuca, P, Bruglia, M, Ciamei, M, Genghini, S, Zannoni, C, Rangel, G, Salvi, L, Zappaterreno, A, Cordone, S, Simonelli, P, Meggiorini, M, Frasheri, A, Di Pippo, C, Maglio, C, Mazzitelli, G, Rinaldi, M, Galli, A, Romano, M, D'Angelo, P, Suraci, C, Bacci, S, Palena, A, Genovese, S, Mancino, M, Rondinelli, M, Capone, F, Calabretto, E, Bulgheroni, M, Bucciarelli, L, Ceccarelli, E, Fondelli, C, Santacroce, C, Guarino, E, Nigi, L, Lalli, C, Di Vizia, G, Scarponi, M, Montani, V, Di Bernardino, P, Romagni, P, Dolcetti, K, Forte, E, Tamburo, L, Perin, P, Prinzis, T, Gruden, G, Bruno, G, Zucco, C, Perotta, M, Marena, S, Monsignore, S, Panero, F, Ponzi, F, Carpinteri, R, Casagrande, M, Coletti, M, Balini, A, Filopanti, M, Madaschi, S, Pulcina, A, Grimaldi, F, Venturini, G, Agus, S, Pagnutti, S, Guidotti, F, Cavarape, A, Cigolini, M, Pichiri, I, Brangani, C, Fainelli, G, Tomasetto, E, Zoppini, G, Galletti, A, Perrone, D, Capra, C, Bianchini, F, Ceseri, M, Di Nardo, B, Sasso, E, Bartolomei, B, Suliman, I, Fabbri, G, Romano, G, Maturo, N, Nunziata, G, Capobianco, G, De Simone, G, Villa, V, Rota, G, Pentangelo, C, Carbonara, O, Caiazzo, G, Cutolo, M, Sorrentino, T, Mastrilli, V, Amelia, U, Masi, S, Corigliano, G, Gaeta, I, Armentano, V, Calatola, P, Capuano, G, Angiulli, B, Auletta, P, Petraroli, E, Iodice, C, Agrusta, M, Vaccaro O., Masulli M., Nicolucci A., Bonora E., Del Prato S., Maggioni A. P., Rivellese A. A., Squatrito S., Giorda C. B., Sesti G., Mocarelli P., Lucisano G., Sacco M., Signorini S., Cappellini F., Perriello G., Babini A. C., Lapolla A., Gregori G., Giordano C., Corsi L., Buzzetti R., Clemente G., Di Cianni G., Iannarelli R., Cordera R., La Macchia O., Zamboni C., Scaranna C., Boemi M., Iovine C., Lauro D., Leotta S., Dall'Aglio E., Cannarsa E., Tonutti L., Pugliese G., Bossi A. C., Anichini R., Dotta F., Di Benedetto A., Citro G., Antenucci D., Ricci L., Giorgino F., Santini C., Gnasso A., De Cosmo S., Zavaroni D., Vedovato M., Consoli A., Calabrese M., di Bartolo P., Fornengo P., Riccardi G., D'Angelo F., Giansanti R., Tanase L., Lanari L., Testa I., Pancani F., Ranchelli A., Vagheggi P., Scatona A., Fontana L., Laviola L., Tarantino L., Ippolito C., Gigantelli V., Manicone M., Conte E., Trevisan R., Rota R., Dodesini A. R., Reggiani G. M., Montesi L., Mazzella N., Forlani G., Caselli C., Di Luzio R., Mazzotti A., Aiello A., Barrea A., Musto A., D'Amico F., Sinagra T., Longhitano S., Trowpea V., Sparti M., Italia S., Lisi E., Grasso G., Pezzino V., Insalaco F., Carallo C., Scicchitano C., De Franceschi M. S., Calbucci G., Ripani R., Cuneo G., Corsi S., Romeo F., Lesina A., Comoglio M., Bonetto C., Robusto A., Nada E., Asprino V., Cetraro R., Impieri M., Lucchese G., Donnarumma G., Tizio B., Lenza L., Paraggio P., Tomasi F., Dozio N., Scalambra E., Mannucci E., Lamanna C., Cignarelli M., Macchia O. L., Fariello S., Sorrentino M. R., Franzetti I., Radin R., Annunziata F., Bonabello L. A., Durante A., Dolcino M., Gallo F., Mazzucchelli C., Aleo A., Melga P., Briatore L., Maggi D., Storace D., Cecoli F., D'Ugo E., Pupillo M., Baldassarre M. P. A., Salvati F., Minnucci A., De Luca A., Zugaro A., Santarelli L., Bosco A., Petrella V., La Verghetta G. G., D'Andrea S., Giuliani A. E., Polidoro W. L., Sperandio A., Sciarretta F., Pezzella A., Carlone A., Potenziani S., Venditti C., Foffi C., Carbone S., Cipolloni L., Moretti C., Leto G., Serra R., Petrachi F., Romano I., Lacaria E., Russo L., Goretti C., Sannino C., Dolci M., Bruselli L., Mori M. L., Baccetti F., Del Freo M., Cucinotta D., Giunta L., Ruffo M. C., Cannizzaro D., Pintaudi B., Perrone G., Pata P., Ragonese F., Lettina G., Mancuso T., Coppolino A., Piatti P. M., Monti L., Stuccillo M., Lucotti P., Setola M., Crippa G. V., Loi C., Oldani M., Bottalico M. L., Pellegata B., Bonomo M., Menicatti L. S. M., Resi V., Bertuzzi F., Disoteo E. O., Pizzi G., Annuzzi G., Capaldo B., Nappo R., Auciello S. M., Turco A. A., Costagliola L., Corte G. D., Vallefuoco P., Nappi F., Vitale M., Cocozza S., Ciano O., Massimino E., Garofalo N., Avogaro A., Guarneri G., Fedele D., Sartore G., Chilelli N. C., Burlina S., Bonsembiante B., Galluzzo A., Torregrossa V., Mancastroppa G., Arsenio L., Cioni F., Caronna S., Papi M., Santeusanio F., Calagreti G., Timi A., Tantucci A., Marino C., Ginestra F., Di Biagio R., Taraborelli M., Miccoli R., Bianchi C., Garofolo M., Politi K. S., Penno G., Livraga S., Calzoni F., Mancastroppa G. L. F., Corsini E., Tedeschi A., Gagliano M. S., Ippolito G., Salutini E., Cervellino F., Natale M., Salvatore V., Zampino A., Sinisi R., Arcangeli A., Zogheri A., Guizzotti S., Longo R., Pellicano F., Scolozzi P., Termine S., Luberto A., Ballardini G., Trojani C., Mazzuca P., Bruglia M., Ciamei M., Genghini S., Zannoni C., Rangel G., Salvi L., Zappaterreno A., Cordone S., Simonelli P., Meggiorini M., Frasheri A., Di Pippo C., Maglio C., Mazzitelli G., Rinaldi M. E., Galli A., Romano M., D'Angelo P., Suraci C., Bacci S., Palena A. P., Genovese S., Mancino M., Rondinelli M., Capone F., Calabretto E., Bulgheroni M., Bucciarelli L., Ceccarelli E., Fondelli C., Santacroce C., Guarino E., Nigi L., Lalli C., Di Vizia G., Scarponi M., Montani V., Di Bernardino P., Romagni P., Dolcetti K., Forte E., Tamburo L., Perin P. C., Prinzis T., Gruden G., Bruno G., Zucco C., Perotta M., Marena S., Monsignore S., Panero F., Ponzi F., Carpinteri R., Casagrande M. L., Coletti M. F., Balini A., Filopanti M., Madaschi S., Pulcina A., Grimaldi F., Venturini G., Agus S., Pagnutti S., Guidotti F., Cavarape A., Cigolini M., Pichiri I., Brangani C., Fainelli G., Tomasetto E., Zoppini G., Galletti A., Perrone D., Capra C., Bianchini F., Ceseri M., Di Nardo B., Sasso E., Bartolomei B., Suliman I., Fabbri G., Romano G., Maturo N., Nunziata G., Capobianco G., De Simone G., Villa V., Rota G., Pentangelo C., Carbonara O., Caiazzo G., Cutolo M., Sorrentino T., Mastrilli V., Amelia U., Masi S., Corigliano G., Gaeta I., Armentano V., Calatola P., Capuano G., Angiulli B., Auletta P., Petraroli E., Iodice C. E., and Agrusta M.
Abstract: Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and previous cardiovascular events, to add-on pioglitazone (15–45 mg) or a sulfonylurea (5–15 mg glibenclamide, 2–6 mg glimepiride, or 30–120 mg gliclazide, in accordance with local practice). The trial was unblinded, but event adjudicators were unaware of treatment assignment. The primary outcome, assessed with a Cox proportional-hazards model, was a composite of first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation, assessed in the modified intention-to-treat population (all randomly assigned participants with baseline data available and without any protocol violations in relation to inclusion or exclusion criteria). This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 p
Published: 2017

18. Optimal model-based clustering with multilevel data

Author: Bacci, S, Bartolucci, F, PENNONI, FULVIA, Yoshiro Yamamoto, Takafumi Kubota, Koji Kurihara, Masahiro Mizuta, Miki Nakai, Junji Nakano, Atsuho Nakayama, Makiko Oda, Takuya Ohmori, Kosuke Okusa, Fumitake Sakaori, Kumiko Shiina, Akinobu Takeuchi, Makoto Tomita, Yuki Toyoda, Hiroshi Yadohisa, Satoru Yokoyama, Bacci, S, Bartolucci, F, and Pennoni, F
Subjects: SECS-S/01 - STATISTICA, Expectation-Maximization algorithm, maximum a-posteriori probability, Viterbi algorithm, Educational effectiveness studie
Abstract: In many contexts, sample units are clustered in groups according to a certain criterion, for instance employees in firms, students in classes, or patients in hospitals. These data are analyzed by multilevel models (Goldstein, 2011) and have important applications in the evaluation of public services, particularly in education and health. For instance, it may be of interest to make comparisons between schools or classes at national and international level on the basis of the students’acquired knowledge. Accountability systems in education have been promoted in the statistical literature mainly since the 90’s by Goldstein and Spiegelhalter (1996), who supported the idea that the performance monitoring approach may improve efficiency. In this work, we focus on models in which the multilevel structure is accounted for by a hierarchical set of discrete latent variables, even in the presence of multivariate responses; these latent variables are used to represent the unobserved heterogeneity between clusters (i.e., groups) of units and between units in each cluster, extending the Latent Class (LC) approach (Lazarsfeld and Henry, 1968) to the multilevel setting. In particular, two cases are of interest. The first is when the observed outcomes are polytomous, as they correspond to item responses, and data are collected at the same time occasion. This approach has been applied by many authors in the educational context, see among others Vermunt (2008) and Gnaldi et al. (2016). The second case of interest is when the data have a longitudinal dimension and heterogeneity between units is represented in a dynamic fashion by a Latent Markov (LM) chain, as proposed in Bartolucci et al. (2011); see also Bartolucci et al. (2013). While maximum likelihood estimation through the Expectation-Maximization algorithm (Dempster et al. 1977) of the models mentioned above is already well established, an issue that still deserves attention is that of predicting the latent variables at cluster and individual level on the basis of the observed data. In the LC literature, the Maximum A-Posteriori (MAP) approach is commonly used for this aim; for each latent variable, it consists in selecting the value having the highest posterior probability, which corresponds to the conditional distribution of this variable given the observed data. For the models at issue, the MAP approach may be applied in two different ways: (i) the latent variables at cluster and unit levels are separately dealt with for each cluster and unit; (ii) we first predict the latent variable for each cluster and then we predict each individual-specific latent variable (or variables in longitudinal case) conditional on the value predicted for the corresponding cluster-level latent variable. Both approaches may lead to suboptimal predictions, in the sense that the predictions may not correspond to the MAP probability of all latent variables. A similar problem exists in the LM model literature, where the sequence of latent states predicted by the local decoding method may not correspond to the MAP sequence of latent states that may be found by the global decoding method (Viterbi, 1967, Juang and Rabiner, 1991). We propose an alternative rule for the posterior classification that jointly considers individuals and groups. More in detail, the proposed rule is built by formulating the multilevel LC model in terms of an LM model (Bartolucci et al. 2013) and, then, considering a suitable adaptation of the Viterbi algorithm. The Viterbi algorithm applied in the hidden Markov literature has the advantage to have a linear complexity since it consists in finding the most likely sequence of latent classes on the basis of a forward and a backward recursion. The involved quantities may be interpreted as posterior probabilities by which we allocate each individual and cluster of individuals to a latent class. To illustrate the proposed approach, we show the results of some applications related to two educational effectiveness studies by considering data collected with the purpose to assess differences in the education level. The first dataset is a collection of measures related to the entire Italian population of schools and classes at the end of the compulsory education period (having at least 10 years of education). These Italian data have been collected by the National Institute of Evaluation of the Educational System of Instruction and Training (INVALSI). They refer to the competences assessed in 2009 by a set of multiple choice items which are dichotomously scored and concern Italian reading and grammar and mathematics; the student gender is available as well as the geographical location of the school. Another type of measurement on reading, mathematics, and science competences has been collected on the large-scale assessment surveys TIMSS (Trends in International Mathematics and Science Study) and PIRLS (Progress in International Reading Literacy Study). The surveys have been conducted in 2011 according to a sampling design that also accounts for the geographical area. We consider the achievement scores at the fourth grade when the Italian pupils are 9 to 10 years old. They have been related to a set of covariates collected by the background parents’ questionnaires and by the principals’ questionnaire of the schools (see also Grilli et al. 2016). The data are released according to five achievement scores for each subject and their variability should be due to the estimation process. These scores known as plausible values (Von Davier and Sinharay, 2013) result from the expected quantities calculated by the E step of the EM algorithm and they are an approximation of the conditional distribution of proficiency when the generalized partial credit model (Muraki, 1992) is used to estimate the performance of examinee subgroups. Main references Bartolucci, F., Farcomeni, A., and Pennoni, F. (2013). Latent Markov Models for Longitudinal Data. Chapman and Hall/CRC press, Boca Raton. Bartolucci, F., Pennoni, F., and Vittadini, G. (2011). Assessment of school performance through a multilevel latent Markov Rasch model. Journal of Educational and Behavioral Statistics, 36, 491– 522. Dempster, A. P., Laird, N. M., and Rubin, D. B. (1977). Maximum likelihood from incomplete data via the EM algorithm (with discussion). Journal of the Royal Statistical Society, Series B, 39, 1–38. Gnaldi, M., Bacci, S., and Bartolucci, F. (2016). A multilevel finite mixture item response model to cluster examinees and schools. Advances in Data Analysis and Classification, 10, 53-70. Grilli, L., Pennoni, F., Rampichini, C., and Romeo, I. (2016). Exploiting TIMSS and PIRLS combined data: Multivariate multilevel modelling of student achievement. The Annals of Applied Statistics, 10, 2405-2426. Goldstein, H. (2011). Multilevel Statistical Models, John Wiley & Sons, Chichester, UK. Goldstein, H. and Spiegelhalter, D. J. (1996). League tables and their limitations: Statistical issues in comparisons of institutional performance. Journal of the Royal Statistical Society, Series A, 3, 385-443. Juang, B. H. and Rabiner, L. R. (1991). Hidden Markov models for speech recognition. Technometrics, 33, 251–272. Lazarsfeld, P. F and Henry, N. W. (1968). Latent Structure Analysis. Houghton Mifflin, Boston. Muraki, E. (1992). A generalized partial credit model: Application of the EM algorithm. Applied Psychological Measurement, 16, 159-177. Vermunt, J. K. (2008). Multilevel latent variable modeling: an application in education testing, Austrian Journal of Statistics, 37, 285–299. Viterbi, A. J. (1967). Error bounds for convolutional codes and an asymptotically optimum decoding algorithm. IEEE Transactions on Information Theory, 13, 260–269. Von Davier, M. and Sinharay, S. (2013). Analytics in international large-scale assessments: Item response theory and population models. Handbook of international large-scale assessment: Background, technical issues, and methods of data analysis, 155-174
Published: 2017

19. A new possible treatment for skin fibrosis with blue light: an in vitro study

Author: Magni G, Rossi F, Tatini F, Fraccalvieri M, Coppi E, Cherchi F, Pugliese AM, Alfieri D, Tripodi C, Targetti L, Bacci S, De Siena G, Cicchi, Pavone F, and e Pini R
Subjects: fibroblasts, fibrosis, wound healing, blue light
Abstract: Wound healing is a dynamic process consisting in four overlapped phases: haemostasis, inflammation, proliferation and remodelling. In our previous in vivo studies on superficial abrasions model, we analysed some cellular type of inflammatory infiltration and tissue remodelling after healing in treated and untreated samples with blue LED light. We pointed out that the blue light carried out an early enter in inflammatory phase and it accelerates the differentiation of fibroblasts into myofibroblasts, improving collagen morphology, leading to a faster healing of the treated tissues. Fibroblasts are the main cells involved in collagen deposition and their overactivity conducts on scars formation and keloid development. The purpose of this work is to investigate the effects of blue light on fibroblasts. In our in vitro studies we irradiated with a blue light primary culture from human keloid fibroblasts which are then analysed by the use of WST8 and SRB assays, electrophysiology and confocal microscopy in order to assess its influence on cells viability and metabolism, membrane potential response and myofibroblast activity. Results show that the blue light has an irradiation time- dependent modulation effect on keloids fibroblasts metabolism but not on viability, and that after irradiation there is a membrane potential response.
Published: 2018

20. Immunohistochemical localization of Langerhans cells as a tool for vitality in hanging mark wounds: a pilot study

Author: Focardi, M., primary, Puliti, E., additional, Grifoni, R., additional, Palandri, M., additional, Bugelli, V., additional, Pinchi, V., additional, Norelli, G.A., additional, and Bacci, S., additional
Published: 2019
Full Text: View/download PDF

21. Immunohistochemical localization of Langerhans cells as a tool for vitality in hanging mark wounds: a pilot study.

Author: Focardi, M., Puliti, E., Grifoni, R., Palandri, M., Bugelli, V., Pinchi, V., Norelli, G.A., and Bacci, S.
Subjects: LANGERHANS cells, VITALITY, DIGITAL images, PILOT projects, HANGING (Death)
Abstract: Hanging deaths are common and characterized by their brief survival time. Macroscopic and histological exams are frequently unable to distinguish vital lesions from post-mortem lesions. This pilot study investigates the dendritic and mast cells in hanging marks to establish vitality lesions. Skin specimens were taken from vital wounds, ligature marks, and post-mortem lesions. Cryosections were stained for haematoxylin eosin, avidin, CD1a and MHC class II+ antigens and examined under light or fluorescence microscopies. Using digitized photomicrographs the images were then analysed. Differences were found in the Langerhans cells and epidermal MHC density, the vital lesions and ligature marks and the other specimens. The results may prove useful in forensic practice when neither macro nor microscopic objective evidence of vitality is available. The results could very possibly support the hypothesis that the amount of time it takes to die from hanging is less than currently believed (< 5 min). [ABSTRACT FROM AUTHOR]
Published: 2020
Full Text: View/download PDF

22. BMI correlates with pulse pressure in offspring of patients with type 2 diabetes and albuminuria

Author: Bacci, S., primary, di Lorenzo, A., additional, Greco, E.V., additional, Tinti, M.G., additional, Rauseo, A., additional, Palena, A.P., additional, Vendemiale, G., additional, and De Cosmo, S., additional
Published: 2018
Full Text: View/download PDF

23. Optimal model-based clustering with multilevel data

Author: Yoshiro Yamamoto, Takafumi Kubota, Koji Kurihara, Masahiro Mizuta, Miki Nakai, Junji Nakano, Atsuho Nakayama, Makiko Oda, Takuya Ohmori, Kosuke Okusa, Fumitake Sakaori, Kumiko Shiina, Akinobu Takeuchi, Makoto Tomita, Yuki Toyoda, Hiroshi Yadohisa, Satoru Yokoyama, Bacci, S, Bartolucci, F, Pennoni, F, PENNONI, FULVIA, Yoshiro Yamamoto, Takafumi Kubota, Koji Kurihara, Masahiro Mizuta, Miki Nakai, Junji Nakano, Atsuho Nakayama, Makiko Oda, Takuya Ohmori, Kosuke Okusa, Fumitake Sakaori, Kumiko Shiina, Akinobu Takeuchi, Makoto Tomita, Yuki Toyoda, Hiroshi Yadohisa, Satoru Yokoyama, Bacci, S, Bartolucci, F, Pennoni, F, and PENNONI, FULVIA
Abstract: In many contexts, sample units are clustered in groups according to a certain criterion, for instance employees in firms, students in classes, or patients in hospitals. These data are analyzed by multilevel models (Goldstein, 2011) and have important applications in the evaluation of public services, particularly in education and health. For instance, it may be of interest to make comparisons between schools or classes at national and international level on the basis of the students’acquired knowledge. Accountability systems in education have been promoted in the statistical literature mainly since the 90’s by Goldstein and Spiegelhalter (1996), who supported the idea that the performance monitoring approach may improve efficiency. In this work, we focus on models in which the multilevel structure is accounted for by a hierarchical set of discrete latent variables, even in the presence of multivariate responses; these latent variables are used to represent the unobserved heterogeneity between clusters (i.e., groups) of units and between units in each cluster, extending the Latent Class (LC) approach (Lazarsfeld and Henry, 1968) to the multilevel setting. In particular, two cases are of interest. The first is when the observed outcomes are polytomous, as they correspond to item responses, and data are collected at the same time occasion. This approach has been applied by many authors in the educational context, see among others Vermunt (2008) and Gnaldi et al. (2016). The second case of interest is when the data have a longitudinal dimension and heterogeneity between units is represented in a dynamic fashion by a Latent Markov (LM) chain, as proposed in Bartolucci et al. (2011); see also Bartolucci et al. (2013). While maximum likelihood estimation through the Expectation-Maximization algorithm (Dempster et al. 1977) of the models mentioned above is already well established, an issue that still deserves attention is that of predicting the latent variables at cluster
Published: 2017

24. Profiles of students on account of complex problem solving strategies

Author: Gnaldi, M., Bacci, S., Greiff, Samuel, Kunze, Thiemo, Gnaldi, M., Bacci, S., Greiff, Samuel, and Kunze, Thiemo
Published: 2017

25. Profiles of students on account of complex problem solving strategies exploited via log-data

Author: Gnaldi, M., Bacci, S., Greiff, Samuel, Kunze, Thiemo, Gnaldi, M., Bacci, S., Greiff, Samuel, and Kunze, Thiemo
Published: 2017

26. The effect of employment condition on perceived health status in Italy in the period 2009-2012

Author: Minelli, L, primary, Seracini, M, additional, Bacci, S, additional, Bartolucci, F, additional, and Chiavarini, M, additional
Published: 2016
Full Text: View/download PDF

27. Sex differences in cardiovascular disease and cardiovascular risk estimation in patients with type 1 diabetes

Author: Alessandra Dei Cas, Raffaella Aldigeri, Alessandro Mantovani, Maria Masulli, Luisa Palmisano, Franco Cavalot, Katia Bonomo, Marco Giorgio Baroni, Efisio Cossu, Gisella Cavallo, Flavia Agata Cimini, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Roberto Trevisan, Mario Luca Morieri, Riccardo Maria Pollis, Giovanni Targher, Saula Vigili de Kreutzenberg, Dei Cas, A, Aldigeri, R, Mantovani, A, Masulli, M, Palmisano, L, Cavalot, F, Bonomo, K, Baroni, M, Cossu, E, Cavallo, G, Cimini, F, Buzzetti, R, Mignogna, C, Leonetti, F, Bacci, S, Trevisan, R, Morieri, M, Pollis, R, Targher, G, and Vigili de Kreutzenberg, S
Subjects: cardiovascular risk, Endocrinology, Type 1 diabete, Endocrinology, Diabetes and Metabolism, Biochemistry (medical), Clinical Biochemistry, gender, CVD, Biochemistry
Abstract: Context Patients with type 1 diabetes (T1D) have higher cardiovascular disease (CVD) risk than the general population. Objective This observational study aims to evaluate sex-related differences in CVD prevalence and CVD risk estimates in a large cohort of T1D adults. Methods We conducted a multicenter, cross-sectional study involving 2041 patients with T1D (mean age 46 years; 44.9% women). In patients without pre-existing CVD (primary prevention), we used the Steno type 1 risk engine to estimate the 10-year risk of developing CVD events. Results CVD prevalence (n = 116) was higher in men than in women aged ≥55 years (19.2 vs 12.8%, P = .036), but comparable between the 2 sexes in those aged Conclusion Both men and women with T1D are at high CVD risk. The 10-year estimated CVD risk was higher in men aged
Published: 2023

28. Multilevel Model-Based Clustering: A New Proposal of Maximum-A-Posteriori Assignment

Author: Silvia Bacci, F Pennoni, Francesco Bartolucci, Imaizumi, T, Okada, A, Miyamoto, S, Sakaori, F, Yamamoto, Y, Vichi, M, Bacci, S, Bartolucci, F, and Pennoni, F
Subjects: Italian National Institute for the Evaluation of the Educational System, business.industry, Computer science, Multilevel model, Context (language use), Latent variable, Machine learning, computer.software_genre, Class (biology), Multilevel Latent Class model, ComputingMethodologies_PATTERNRECOGNITION, Trends in International Mathematics and Science Study (TIMSS) and Progress on International Reading Literacy Study (PIRLS), SECS-S/01 - STATISTICA, Maximum a posteriori estimation, Artificial intelligence, Latent variable model, Cluster analysis, business, Categorical variable, computer, Expectation-Maximization (EM) algorithm, Viterbi algorithm
Abstract: We deal with the problem of latent variable prediction in the context of multilevel latent class models for categorical responses provided by individuals nested in groups. In particular, we propose a posterior assignment rule that jointly predicts the individual- and group-level latent variables. This proposal is alternative to the common maximum- a-posteriori rule, which is based on first predicting the latent variables at cluster level and, then, those at individual level. To illustrate the proposal, we show the results of two simulation studies and two applications on data related to the national and the international assessment of student skills.
Published: 2020

29. Measurement of Inter-Individual Variability in Assessing the Quality of Life in Respondents with Celiac Disease

Author: Maria Iannario, Rosa Fabbricatore, Silvia Bacci, Daniela Caso, Bacci, S., Caso, D., Fabbricatore, R., and Iannario, M.
Subjects: Ordinal data, multidimensional model, behavioral disciplines and activities, 01 natural sciences, Dysphoria, 010104 statistics & probability, Social support, 0504 sociology, Quality of life, Item response theory, medicine, Pharmacology (medical), 0101 mathematics, Graded response model, 05 social sciences, 050401 social sciences methods, item response theory, Polytomous Rasch model, Latent class model, ordinal data, Distress, quality of life, medicine.symptom, Psychology, latent class model, Clinical psychology
Abstract: Quality of life of Celiac Disease (CD) patients is affected by constraints in their physical, social and emotional behaviour. Our objective is to assess differences in two relevant dimensions of the Celiac Quality of Life (CQoL) scale, Limitations due to the disease and Dysphoria (i.e., feelings of depression and discomfort), in relation to the perceived social support and some individual and disease-related characteristics. The paper exploits suitable unidimensional Item Response Theory (IRT) models to individually analyse the two mentioned dimensions of the CQoL and Multidimensional Latent Class IRT models for ordinal polytomous items in order to detect sub-populations of CD patients that are homogenous with respect to the perceived CQoL. The latter methods allow to address patients with similar characteristics to the same treatment, performing at the same time a more tailored overture to health promotion programmes. The analysis extracts the relevant patterns and relations among CD patients, disentangling respondents receiving CD diagnosis in adolescence or adult age rather than in childhood (the first perceive high levels of Limitations and Dysphoria), patients with high perceived social support, a factor influencing in a positive way motivation to engage in management of CD-related distress and psychological well-being, and participants who are married or cohabiting. The latter report higher latent trait levels.
Published: 2020

30. Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study

Author: Angela A. Rivellese, Simonetta Bacci, S. Cocozza, Saula Vigili de Kreutzenberg, Marco Giorgio Baroni, Anna Solini, Angelo Avogaro, Alessandra Boi, Rossella Nappo, Edoardo Vitolo, Vigili de Kreutzenberg, S, Solini, A, Vitolo, E, Boi, A, Bacci, S, Cocozza, S, Nappo, R, Rivellese, A, Avogaro, A, and Baroni, Mg
Subjects: Male, Endocrinology, Diabetes and Metabolism, Stress testing, Coronary Disease, Type 2 diabetes, 030204 cardiovascular system & hematology, 0302 clinical medicine, Endocrinology, Diabetes complications, Silent coronary heart disease ischemia Type 2 diabetes CHD diagnosis Electrocardiogram Diabetes complications Positive predictive value, Medicine, Outpatient clinic, Mass Screening, CHD diagnosis, Electrocardiogram, Positive predictive value, Silent coronary heart disease ischemia, Internal Medicine, Middle Aged, Prognosis, Diabetes and Metabolism, Cohort, Cardiology, Female, medicine.symptom, Endocrine, Type 2, Algorithms, Adult, medicine.medical_specialty, 030209 endocrinology & metabolism, Asymptomatic, Diagnostic Techniques, Endocrine, 03 medical and health sciences, Predictive Value of Tests, Diabetes mellitus, Internal medicine, Diabetes Mellitus, Humans, cardiovascular diseases, Aged, business.industry, Microangiopathy, medicine.disease, Coronary heart disease, Asymptomatic Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Follow-Up Studies, Diagnostic Techniques, business
Abstract: Aims The cost-effectiveness of screening for silent coronary heart disease (CHD) in type 2 diabetes (DM2) is still debated. Methods We applied a diagnostic algorithm for silent CHD detection, in a cohort of 102 asymptomatic DM2 subjects (57 ± 7 years), attending 5 Italian outpatient clinics, to verify its predictive value. The risk of silent CHD was calculated considering classical risk factors, and presence of microangiopathy/macroangiopathy. Patients were divided in 3 groups, i.e. group 1: normal ECG and low silent CHD risk; group 2: abnormal ECG, irrespective of silent CHD risk; group 3: high silent CHD risk, irrespective of ECG. To group 2 and 3, a functional test was recommended and performed in 78% of patients. Results Silent CHD prevalence was similar in group 2 and 3 (25 vs. 17% respectively; p = 0.495). However, evaluating the entire cohort, a significant higher prevalence of silent CHD was observed in subjects with abnormal vs. normal ECG (23 vs. 4%; P = 0.004), but not in subjects with high vs. low pre-test silent CHD risk (14 vs. 9%; p = 0.472). Conclusions An abnormal ECG was a strong, independent predictor of silent CHD (OR 8.9; CI 1.27–62.5; p = 0.028) in DM2. Therefore, a functional stress testing should be considered in DM2 patients with ECG abnormalities.
Published: 2017

31. Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study

Author: Vitale, M., Masulli, M., Rivellese, A. A., Bonora, E., Cappellini, F., Nicolucci, Andrea, Squatrito, S., Antenucci, D., Barrea, A., Bianchi, C., Bianchini, F., Fontana, L., Fornengo, P., Giorgino, F., Gnasso, A., Mannucci, E., Mazzotti, A., Nappo, R., Palena, A. P., Pata, P., Perriello, G., Potenziani, S., Radin, R., Ricci, L., Romeo, F., Santini, C., Scarponi, M., Serra, Riccardo, Timi, A., Turco, A. A., Vedovato, M., Zavaroni, D., Grioni, S., Riccardi, G., Vaccaro, O., Rivellese, Angela Albarosa, Cocozza, Sara, Auciello, Stefania, Turco, Anna Amelia, Bonora, Enzo, Cigolini, Massimo, Pichiri, Isabella, Brangani, Corinna, Tomasetto, Elena, Perriello, Gabriele, Timi, Alessia, Squatrito, Sebastiano, Sinagra, Tiziana, Longhitano, Sara, Tropea, Vanessa, Ballardini, Giorgio, Babini, Anna Carla, Ripani, Raffaella, Gregori, Giovanna, Dolci, Maria, Bruselli, Laura, Salutini, Isabella, Mori, Mary, Baccetti, Fabio, Lapolla, Annunziata, Sartore, Giovanni, Burlina, Silvia, Chilelli, Nino Cristiano, Buzzetti, Raffaella, Venditti, Chiara, Potenziani, Stella, Carlone, Angela, Galluzzoâ€&nbsp, Aldo, Giordano, Carla, Torregrossa, Vittoria, Corsi, Laura, Cuneo, Giacomo, Corsi, Simona, Tizio, Biagio, Clemente, Gennaro, Citro, Giuseppe, Natale, Maria, Salvatore, Vita, Di Cianni, Graziano, Lacaria, Emilia, Russo, Laura, Iannarelli, Rossella, de Gregorio, Antonella, Sciarretta, Filomena, Dâ€™Andrea, Settimio, Montani, Valeria, Cannarsa, Emanuela, Dolcetti, Katia, Cordera, Renzo, Bonabello, Laura Affinito, Mazzucchelli, Chiara, Giorda, Carlo Bruno, Romeo, Francesco, Bonetto, Caterina, Antenucci, Daniela, Baldassarre, Maria Pompea Antonia, Iovine, Ciro, Nappo, Rossella, Ciano, Ornella, Dallâ€™Aglio, Elisabetta, Mancastroppa, Giovanni, Grimaldi, Franco, Tonutti, Laura, Boemi, Massimo, Dâ€™Angelo, Federica, Leotta, Sergio, Fontana, Lucia, Lauro, Davide, Rinaldi, Maria Elena, Cignarelli, Mauro, la Macchia, Olga, Fariello, Stefania, Tomasi, Franco, Zamboni, Chiara, Dozio, Nicoletta, Trevisan, Roberto, Scaranna, Cristiana, Del Prato, Stefano, Miccoli, Roberto, Bianchi, Cristina, Garofolo, Monia, Pugliese, Giuseppe, Salvi, Laura, Rangel, Graziela, Vitale, Martina, Anichini, Roberto, Tedeschi, Anna, Corsini, Elisa, Cucinotta, Domenico, Di Benedetto, Antonino, Giunta, Loretta, Ruffo, Maria Concetta, Bossi, Antonio Carlo, Carpinter, Rita, Dotta, Francesco, Ceccarelli, Elena, Bartolo, Paolo Di, Caselli, Chiara, Luberto, Alessandra, Santini, Costanza, Mazzotti, Arianna, Calbucci, Giovanni, Consoli, Agostino, Ginestra, Federica, Calabrese, Maria, Zogheri, Alessia, Ricci, Lucia, Giorgino, Francesco, Laviola, Luigi, Ippolito, Claudia, Tarantino, Lucia, Avogaro, Angelo, Vedovato, Monica, Gnasso, Agostino, Carallo, Claudio, Scicchitano, Caterina, Zavaroni, Donatella, Livraga, Stefania, Perin, Paolo Cavallo, Forrnengo, Paolo, Prinzis, Tania, de Cosmo, Salvatore, Palena, Antonio Pio, Bacci, Simonetta, Mannucci, Edoardo, Lamanna, Caterina, Pata, Pietro, Lettina, Gabriele, Aiello, Antimo, Barrea, Angelina, Lalli, Carlo, Scarponi, Maura, Franzetti, Ivano, Radin, Raffaella, Serra, Rosalia, Petrachi, Francesca, Asprino, Vincenzo, Capra, Claudio, Forte, Elisa, Reggiani, Giulio Marchesini, Forlani, Gabriele, Montesi, Luca, Mazzella, Natalia, Piatti, Pier Marco, Monti, Lucilla, Stuccillo, Michela, Auletta, Pasquale, Petraroli, Ettore, Capobianco, Giuseppe, Romano, Geremia, Cutolo, Michele, de Simone, Giosetta, Caiazzo, Gennaro, Nunziata, Peppe, Sorrentino, Susy, Amelia, Umberto, Calatola, Pasqualino, Capuano, Gelsomina, Vitale, M, Masulli, M, Rivellese, AA, Bonora, E, Cappellini, F, Nicolucci, A, Squatrito, S, Antenucci, D, Barrea, A, Bianchi, C, Bianchini, F, Fontana, L, Fornengo,P, Giorgino, F, Gnasso, A, Mannucci, Mazzotti, A, Nappo, R, Palena, AP, Pata, P,Perriello, G, Potenziani, S, Radin, R, Ricci, L, Romeo, F, Santini, C, Scarponi, M, Serra, R, Timi, A, Turco, AA, Vedovato, M, Zavaroni, D, Grioni, S, Riccardi, G, Vaccaro, O, TOSCA.IT Study Group., Giordano, C., Rivellese, Aa, Fornengo, P, Mannucci, E, Mazzotti, A, Nappo, R, Palena, Ap, Pata, P, Perriello, G, Turco, Aa, Tosc, A. IT Study Group., Rivellese, A, Palena, A, Turco, A, Cocozza, S, Auciello, S, Cigolini, M, Pichiri, I, Brangani, C, Tomasetto, E, Sinagra, T, Longhitano, S, Tropea, V, Ballardini, G, Babini, A, Ripani, R, Gregori, G, Dolci, M, Bruselli, L, Salutini, I, Mori, M, Baccetti, F, Lapolla, A, Sartore, G, Burlina, S, Chilelli, N, Buzzetti, R, Venditti, C, Carlone, A, Galluzzo, A, Giordano, C, Torregrossa, V, Corsi, L, Cuneo, G, Corsi, S, Tizio, B, Galluzzo, G, Citro, G, Natale, M, Salvatore, V, Di Cianni, G, Lacaria, E, Russo, L, Iannarelli, R, De Gregorio, A, Sciarretta, F, D'Andrea, S, Montani, V, Cannarsa, E, Dolcetti, K, Cordera, R, Bonabello, L, Mazzucchelli, C, Giorda, C, Bonetto, C, Baldassarre, M, Iovine, C, Ciano, O, Dall'Aglio, E, Mancastroppa, G, Grimaldi, F, Tonutti, L, Boemi, M, D'Angelo, F, Leotta, S, Lauro, D, Rinaldi, M, Cignarelli, M, La Macchia, O, Fariello, S, Tomasi, F, Zamboni, C, Dozio, N, Trevisan, R, Scaranna, C, Del Prato, S, Miccoli, R, Garofolo, M, Pugliese, G, Salvi, L, Rangel, G, Anichini, R, Tedeschi, A, Corsini, E, Cucinotta, D, Di Benedetto, A, Giunta, L, Ruffo, M, Bossi, A, Carpinter, R, Dotta, F, Ceccarelli, E, Bartolo, P, Caselli, C, Luberto, A, Calbucci, G, Consoli, A, Ginestra, F, Calabrese, M, Zogheri, A, Laviola, L, Ippolito, C, Tarantino, L, Avogaro, A, Carallo, C, Scicchitano, C, Livraga, S, Perin, P, Forrnengo, P, Prinzis, T, De Cosmo, S, Bacci, S, Lamanna, C, Lettina, G, Aiello, A, Lalli, C, Franzetti, I, Petrachi, F, Asprino, V, Capra, C, Forte, E, Reggiani, G, Forlani, G, Montesi, L, Mazzella, N, Piatti, P, Monti, L, Stuccillo, M, Auletta, P, Petraroli, E, Capobianco, G, Romano, G, Cutolo, M, De Simone, G, Caiazzo, G, Nunziata, P, Sorrentino, S, Amelia, U, Calatola, P, and Capuano, G
Subjects: 0301 basic medicine, Male, Age, BMI, Diabetes, Diet, Flavonoids, Food groups, Geographical area, Intake, Phenolic acids, Polyphenols, TOSCA.IT study, Aged, Antioxidants, Beverages, Cinnamates, Cohort Studies, Cross-Sectional Studies, Databases, Factual, Diabetes Mellitus, Type 2, Female, Flavonoids, Fruit, Glycosides, Humans, Italy, Male, Middle Aged, Nutritive Value, Phenols, Polyphenols, Diet, Diabetic, Diet, Healthy, Patient Compliance, Settore MED/09 - Medicina Interna, Databases, Factual, Cross-sectional study, Medicine (miscellaneous), Type 2 diabetes, Diabete, Antioxidants, Settore MED/13 - Endocrinologia, Food group, Cohort Studies, 0302 clinical medicine, Diet, Diabetic, Medicine, Food science, Glycosides, Age, BMI, Diabetes, Diet, Flavonoids, Food groups, Geographical area, Intake, Phenolic acids, Polyphenols, TOSCA.IT study, Nutrition and Dietetics, Phenolic acid, food and beverages, Middle Aged, Polyphenols, Flavonoids, Phenolic acids, Diabetes, Food groups, Diet, Age, BMI, Geographical area, Intake, TOSCA.IT study, Italy, Tosca,Age,BMI,Diabetes,Diet,Flavonoids,Food groups,Geographical area,Intake,Phenolic acids,Polyphenols,TOSCA.IT study, Cohort, Female, Diet, Healthy, Nutritive Value, Cohort study, Polyphenol, 030209 endocrinology & metabolism, Beverages, 03 medical and health sciences, Phenols, Diabetes mellitus, Humans, Aged, 030109 nutrition & dietetics, business.industry, Anthropometry, medicine.disease, Tosca, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Cinnamates, Fruit, Flavonoid, Patient Compliance, business
Abstract: Purpose: Proper evaluation of polyphenols intake at the population level is a necessary step in order to establish possible associations with health outcomes. Available data are limited, and so far no study has been performed in people with diabetes. The aim of this work was to document the intake of polyphenols and their major food sources in a cohort of people with type 2 diabetes and in socio-demographic subgroups. Methods: We studied 2573 men and women aged 50–75 years. Among others, anthropometry was measured by standard protocol and dietary habits were investigated by food frequency questionnaire (EPIC). The intake of polyphenols was evaluated using US Department of Agriculture and Phenol-Explorer databases. Results: The mean total polyphenol intake was 683.3 ± 5.8 mg/day. Non-alcoholic beverages represented the main food source of dietary polyphenols and provided 35.5% of total polyphenol intake, followed by fruits (23.0%), alcoholic beverages (14.0%), vegetables (12.4%), cereal products and tubers (4.6%), legumes (3.7%) and oils (2.1%); chocolate, cakes and nuts are negligible sources of polyphenols in this cohort. The two most important polyphenol classes contributing to the total intake were flavonoids (47.5%) and phenolic acids (47.4%). Polyphenol intake increased with age and education level and decreased with BMI; furthermore, in the northern regions of Italy, the polyphenol intake was slightly, but significantly higher than in the central or southern regions. Conclusions: The study documents for the first time the intake of polyphenols and their main food sources in people with diabetes using validated and complete databases of the polyphenol content of food. Compared with published data, collected in people without diabetes, these results suggest a lower intake and a different pattern of intake in people with diabetes. © 2016 Springer-Verlag Berlin Heidelberg
Published: 2016
Full Text: View/download PDF

32. Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).

Author: Savulescu C, Prats-Uribe A, Brolin K, Uusküla A, Bergin C, Fleming C, Zvirbulis V, Zavadska D, Szułdrzyński K, Gaio V, Popescu CP, Craiu M, Cisneros M, Latorre-Millán M, Lohur L, McGrath J, Ferguson L, Abolina I, Gravele D, Machado A, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sui J, Kenny C, Krievins D, Barzdina EA, Melo A, Kosa AG, Miron VD, Muñoz-Almagro C, Milagro AM, Bacci S, Kramarz P, and Nardone A
Subjects: Humans, Female, Male, Adult, Prospective Studies, Middle Aged, Vaccine Efficacy statistics & numerical data, Antibodies, Viral blood, Cohort Studies, Europe, Immunization, Secondary, Health Personnel statistics & numerical data, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology
Abstract: Introduction: Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared to the first booster, against laboratory-confirmed SARS-CoV-2 infection in HCWs., Methods: In a prospective cohort study among HCWs from 12 European hospitals, we collected nasopharyngeal or saliva samples at enrolment and during weekly/fortnightly follow-up between October 2022 and May 2023. We estimated rVE of the second versus first COVID-19 vaccine booster dose against SARS-CoV-2 infection, overall, by time since second booster and restricted to the bivalent vaccines only. Using Cox regression, we calculated the rVE as (1-hazard ratio)*100, adjusting for hospital, age, sex, prior SARS-CoV-2 infection and at least one underlying condition., Results: Among the 979 included HCWs eligible for a second booster vaccination, 392 (40 %) received it and 192 (20 %) presented an infection during the study period. The rVE of the second versus first booster dose was -5 % (95 %CI: -46; 25) overall, 3 % (-46; 36) in the 7-89 days after receiving the second booster dose. The rVE was 11 % (-43; 45) when restricted to the use of bivalent vaccines only., Conclusion: The bivalent COVID-19 could have reduced the risk of SARS-CoV-2 infection among HCWs by 11 %. However, we note the limitation of imprecise rVE estimates due to the proportion of monovalent vaccine used in the study, the small sample size and the study being conducted during the predominant circulation of XBB.1.5 sub-lineage. COVID-19 vaccine effectiveness studies in HCWs can provide important evidence to inform the optimal timing and the use of updated COVID-19 vaccines., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: APU reported payment under EMA DARWIN EU project outside of the submitted work. MLM, AM, LCC reported additional support received from ISIDORe (EATRIS) Network for carrying out the local SARS-CoV-2 sequencing. CPP reported speaker fees from Pfizer and MSD. SAF reported speaker fees from and participation in Advisory board of Pfizer, MSD and Gilead. CMA reported speaker fees from MSD, Pfizer and Sanofi. JS reported support for attending ESID conference 2022 from Takeda Pharmaceutical. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Published: 2025
Full Text: View/download PDF

33. Mast cells and wound healing: Still an open question.

Author: Fernández-Guarino M and Bacci S
Subjects: Humans, Animals, Inflammation immunology, Mast Cells immunology, Wound Healing immunology, Wound Healing physiology
Abstract: Mast cells, which originate from the bone marrow, possess the ability to secrete a diverse array of active molecules. These molecules include mediators (histamine, heparin), which have been identified for decades and are stored in specific granules, as well as small molecules generated instantaneously in response to stimulation (membrane lipid derivatives, nitric oxide), and a multitude of multifunctional cytokines that are secreted constitutively. Activated mast cells participate in the regulation of the local immune response and exert control over critical events of inflammation and healing with the assistance of a vast array of mediators. The involvement of these cell types in inflammatory states suggests that mast cells may function as sentinels that activate local immune processes in response to various types of stimuli and the entry of antigens. Moreover, due to their proximity to nerve fibers and reactivity to a variety of neurotransmitters, mast cells are among the cells that may facilitate local neuroimmune interactions. With this in mind, it is necessary to consider their participation in the repair of injuries in both acute and chronic conditions., (©The Author(s) 2024. Open Access. This article is licensed under a Creative Commons CC-BY International License.)
Published: 2025
Full Text: View/download PDF

34. Molecular Biomarkers in Cutaneous Photodynamic Therapy: A Comprehensive Review.

Author: Naharro-Rodriguez J, Bacci S, and Fernandez-Guarino M
Abstract: Background/objectives: Photodynamic therapy (PDT) is widely utilized in dermatology for the treatment of various skin conditions. Despite its effectiveness, the exact biomolecular changes underlying therapeutic outcomes remain only partially understood. This review, through a transversal approach, aims to provide an in-depth exploration of molecular biomarkers involved in PDT, evaluate its underlying mechanisms, and examine how these insights can contribute to enhanced treatment protocols and personalized therapy approaches., Methods: A narrative review of the literature was conducted, targeting peer-reviewed articles and clinical trials that focus on PDT and its molecular biomarker effects on dermatological conditions. The databases searched included PubMed, Scopus, and Web of Science, and the inclusion criteria encompassed original research articles, systematic reviews, and meta-analyses in English., Results: PDT effectively reduces the expression of critical biomarkers such as p53, Cyclin D1, and Ki-67 in AK and other cancerous lesions, leading to reduced cell proliferation and increased apoptosis. Additionally, PDT promotes extracellular matrix remodeling and stimulates collagen production, which has a rejuvenating effect on the skin and a promising role in the treatment of chronic wounds., Conclusions: PDT represents a powerful and versatile treatment option for various dermatological conditions due to its ability to target cellular pathways involved in proliferation and apoptosis. Further research into optimizing treatment parameters and combining PDT with other targeted therapies may enhance patient outcomes, reduce resistance, and pave the way for more individualized therapeutic approaches in dermatology.
Published: 2024
Full Text: View/download PDF

35. Laser Emission at 675 nm: Molecular Counteraction of the Aging Process.

Author: Notari L, Pieri L, Cialdai F, Fusco I, Risaliti C, Madeddu F, Bacci S, Zingoni T, and Monici M
Abstract: Background/objectives: Many lasers applied in skin rejuvenation protocols show emissions with wavelengths falling in the red or near-infrared (NIR) bands. To obtain further in vitro data on the potential therapeutic benefits regarding rejuvenation, we employed a 675 nm laser wavelength on cultured human dermal fibroblasts to understand the mechanisms involved in the skin rejuvenation process's signaling pathways by analyzing cytoskeletal proteins, extracellular matrix (ECM) components, and membrane integrins., Methods: Normal human dermal fibroblasts (NHDFs) were irradiated with a 675 nm laser 24 h after seeding, and immunofluorescence microscopy and Western blotting were applied., Results: The results demonstrate that the laser treatment induces significant changes in human dermal fibroblasts, affecting cytoskeleton organization and the production and reorganization of ECM molecules. The cell response to the treatment appears to predominantly involve paxillin-mediated signaling pathways., Conclusions: These changes suggest that laser treatment can potentially improve the structure and function of skin tissue, with interesting implications for treating skin aging.
Published: 2024
Full Text: View/download PDF

36. Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021-May 2023.

Author: Savulescu C, Prats-Uribe A, Brolin K, Lovrić Makarić Z, Uusküla A, Panagiotakopoulos G, Bergin C, Fleming C, Agodi A, Bonfanti P, Murri R, Zvirbulis V, Zavadska D, Szuldrzynski K, Machado A, Popescu CP, Craiu M, Cisneros M, Latorre-Millán M, Petrović G, Lohur L, Tryfinopoulou K, McGrath J, Ferguson L, Barchitta M, Spolti A, de Gaetano Donati K, Abolina I, Gravele D, Gaio V, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sarajlić G, Amerali M, Sui J, Kenny C, Rapisarda V, Rossi M, Lamonica S, Krievins D, Barzdina EA, Palmira Amaral A, Kosa AG, Miron VD, Muñoz-Almagro C, Milagro AM, Bacci S, Kramarz P, Nardone A, and The Vebis Hcw Ve Study Group
Abstract: Background: European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. Methods: HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up. We measured the incidence during pre-Delta (2 May-6 September 2021), Delta (7 September-14 December 2021), and Omicron (15 December 2021-2 May 2023) waves. Using Cox regression, we measured the relative vaccine effectiveness (rVE) of the first COVID-19 booster dose versus primary course alone during Delta and Omicron waves. Results: We included a total of 3015 HCWs. Participants were mostly female (2306; 79%), with a clinical role (2047; 68%), and had a median age of 44 years. The overall incidence of SARS-CoV-2 infection was 3.01/10,000 person-days during pre-Delta, 4.21/10,000 during Delta, and 23.20/10,000 during Omicron waves. rVE was 59% (95% CI: -25; 86) during Delta and 22% (1; 39) during Omicron waves. rVE was 51% (30; 65) 7-90 days after the first booster dose during the Omicron wave. Conclusions: The incidence of SARS-CoV-2 infection among HCWs was higher during the Omicron circulation period. The first COVID-19 vaccine booster provided additional protection against SARS-CoV-2 infection compared to primary course vaccination when recently vaccinated <90 days. This multi-country HCW cohort study addressing infection as the main outcome is crucial for informing public health interventions for HCWs.
Published: 2024
Full Text: View/download PDF

37. Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.

Author: Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, and Kissling E
Subjects: Humans, Aged, Female, Male, Europe epidemiology, Case-Control Studies, Aged, 80 and over, Primary Health Care, Vaccination, COVID-19 prevention & control, COVID-19 immunology, COVID-19 epidemiology, SARS-CoV-2 immunology, SARS-CoV-2 genetics, Vaccine Efficacy, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage
Abstract: We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

38. Photodynamic Therapy 2.0.

Author: Kang K and Bacci S
Abstract: In 1903, Von Tappeiner and Jesionek [...].
Published: 2024
Full Text: View/download PDF

39. Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].

Author: Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Paula Rodrigues A, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, and Kissling E
Published: 2024
Full Text: View/download PDF

40. Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24.

Author: Savulescu C, Prats-Uribe A, Brolin K, Uusküla A, Bergin C, Fleming C, Murri R, Zvirbulis V, Zavadska D, Gaio V, Popescu CP, Hrisca R, Cisneros M, Latorre-Millán M, Lohur L, McGrath J, Ferguson L, De Gaetano Donati K, Abolina I, Gravele D, Machado A, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sui J, Kenny C, Santangelo R, Krievins D, Barzdina EA, Valadas Henriques C, Kosa AG, Pohrib SM, Muñoz-Almagro C, Milagro A, Bacci S, and Nardone A
Subjects: Humans, Europe epidemiology, Female, Adult, Male, Prospective Studies, Middle Aged, Vaccine Efficacy, Seasons, Incidence, Cohort Studies, Hospitals, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, COVID-19 prevention & control, COVID-19 epidemiology, SARS-CoV-2 immunology, Health Personnel statistics & numerical data, Vaccination statistics & numerical data
Abstract: COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95% CI: -17 to 48), 49% (95% CI: -8 to 76) before and -11% (95% CI: -84 to 34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention.
Published: 2024
Full Text: View/download PDF

41. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.

Author: Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, and Kissling E
Subjects: Humans, Europe epidemiology, Female, Male, Middle Aged, Adult, Case-Control Studies, Aged, Young Adult, Adolescent, Vaccination methods, Vaccination statistics & numerical data, Immunization Programs, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, Primary Health Care, Vaccine Efficacy
Abstract: In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case-control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26-53 %) overall, 48 % (95 % CI: 31-61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3-49 %) at 6-14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

42. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.

Author: Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, and Kissling E
Subjects: Humans, Aged, Female, Europe epidemiology, Male, Middle Aged, Case-Control Studies, Aged, 80 and over, Vaccination statistics & numerical data, European People, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines therapeutic use, Vaccine Efficacy, SARS-CoV-2 immunology, Seasons
Abstract: Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns., Objective: To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection (with all circulating viruses and XBB lineage in particular) among people aged 60 years or older in Europe, and to compare different CVE approaches across the exposed and reference groups used., Design, Setting, and Participants: This case-control study obtained data from VEBIS (Vaccine Effectiveness, Burden and Impact Studies), a multicenter study that collects COVID-19 and influenza data from 11 European sites: Croatia; France; Germany; Hungary; Ireland; Portugal; the Netherlands; Romania; Spain, national; Spain, Navarre region; and Sweden. Participants were primary care patients aged 60 years or older with acute respiratory infection symptoms who were recruited at the 11 sites after the start of the COVID-19 vaccination campaign from September 2022 to August 2023. Cases and controls were defined as patients with positive and negative, respectively, reverse transcription-polymerase chain reaction (RT-PCR) test results., Exposures: The exposure was COVID-19 vaccination. The exposure group consisted of patients who received a COVID-19 vaccine during the autumn and winter 2022 to 2023 vaccination campaign and 14 days or more before symptom onset. Reference group included patients who were not vaccinated during or in the 6 months before the 2022 to 2023 campaign (seasonal CVE), those who were never vaccinated (absolute CVE), and those who were vaccinated with at least the primary series 6 months or more before the campaign (relative CVE). For relative CVE of second boosters, patients receiving their second booster during the campaign were compared with those receiving 1 booster 6 months or more before the campaign., Main Outcomes and Measures: The outcome was RT-PCR-confirmed, medically attended, symptomatic SARS-CoV-2 infection. Four CVE estimates were generated: seasonal, absolute, relative, and relative of second boosters. CVE was estimated using logistic regression, adjusting for study site, symptom onset date, age, chronic condition, and sex., Results: A total of 9308 primary care patients were included, with 1687 cases (1035 females; median [IQR] age, 71 [65-79] years) and 7621 controls (4619 females [61%]; median [IQR] age, 71 [65-78] years). Within 14 to 89 days after vaccination, seasonal CVE was 29% (95% CI, 14%-42%), absolute CVE was 39% (95% CI, 6%-60%), relative CVE was 31% (95% CI, 15% to 44%), and relative CVE of second boosters was 34% (95% CI, 18%-47%) against all SARS-CoV-2 variants. In the same interval, seasonal CVE was 44% (95% CI, -10% to 75%), absolute CVE was 52% (95% CI, -23% to 82%), relative CVE was 47% (95% CI, -8% to 77%), and relative CVE of second boosters was 46% (95% CI, -13% to 77%) during a period of high XBB circulation. Estimates decreased with time since vaccination, with no protection from 180 days after vaccination., Conclusions and Relevance: In this case-control study among older Europeans, all CVE approaches suggested that COVID-19 vaccines administered in autumn and winter 2022 to 2023 offered at least 3 months of protection against symptomatic, medically attended, laboratory-confirmed SARS-CoV-2 infection. The effectiveness of new COVID-19 vaccines against emerging SARS-CoV-2 variants should be continually monitored using CVE seasonal approaches.
Published: 2024
Full Text: View/download PDF

43. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.

Author: Maurel M, Mazagatos C, Goerlitz L, Oroszi B, Hooiveld M, Machado A, Domegan L, Ilić M, Popescu R, Sève N, Martínez-Baz I, Larrauri A, Buda S, Túri G, Meijer A, Gomez V, O'Donnell J, Mlinarić I, Timnea O, Diez AO, Dürrwald R, Horváth JK, Dijkstra F, Rodrigues AP, McKenna A, Filipović SK, Lazar M, Kaczmarek M, Bacci S, and Kissling E
Subjects: Humans, Adolescent, Europe epidemiology, Adult, Middle Aged, Female, Aged, Male, Child, Preschool, Child, Young Adult, Case-Control Studies, Infant, Seasons, Infant, Newborn, Vaccination statistics & numerical data, Respiratory Tract Infections epidemiology, Respiratory Tract Infections diagnosis, Respiratory Tract Infections prevention & control, Influenza Vaccines immunology, Influenza Vaccines administration & dosage, Influenza, Human prevention & control, Influenza, Human epidemiology, Influenza, Human diagnosis, Primary Health Care statistics & numerical data, Vaccine Efficacy
Abstract: Background: Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS primary care European multicentre study end-of-season data to evaluate whether the clinical case definition affected IVE estimates., Methods: We estimated VE using a multicentre test-negative case-control design. We measured VE against any influenza and influenza (sub)types, by age group (0-14, 15-64, ≥65 years) and by influenza vaccine target group, using logistic regression. We estimated IVE among patients meeting the European Union (EU) acute respiratory infection (ARI) case definition and among those meeting the EU influenza-like illness (ILI) case definition, including only sites providing information on specific symptoms and recruiting patients using an ARI case definition (as the EU ILI case definition is a subset of the EU ARI one)., Results: We included 24 319 patients meeting the EU ARI case definition, of whom 21 804 patients (90 %) meet the EU ILI case definition, for the overall pooled VE analysis against any influenza. The overall and influenza (sub)type-specific VE varied by ≤2 % between EU ILI and EU ARI populations., Discussion: Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022-23 influenza season was not affected by use of a different clinical case definition for recruitment, although we recommend investigating whether this holds true for next seasons., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

44. Neuroimmunomodulatory effect of Nitric Oxide on chronic wound healing after photodynamic therapy.

Author: Nardini P, Notari L, Magazzini M, Mariani B, Rossi F, Rossi S, Van Aardt E, Marszalek K, Grandi V, Corsi A, Pimpinelli N, and Bacci S
Subjects: Humans, Neuroimmunomodulation drug effects, Neuroimmunomodulation physiology, Prospective Studies, Nitric Oxide metabolism, Photochemotherapy methods, Photosensitizing Agents pharmacology, Photosensitizing Agents therapeutic use, Wound Healing drug effects, Wound Healing physiology
Abstract: Neuroimmunomodulation is the capacity of the nervous system to regulate immune processes. The existence of neurotransmitter receptors in immune cells enables this phenomenon to take place. Neuronal mediators possess the capacity to direct and control several occurrences during the wound healing process. Nitric oxide (NO) functions as a neuromodulator, playing a crucial role in the regulation of vascular tone and blood pressure with antimicrobial properties. Photodynamic therapy has been shown to augment the function of immune cells involved in the healing process of venous leg ulcers. Nitric oxide can be secreted into the extracellular environment by these cells. In lesions treated with PDT, the synthesis of iNOs (the enzyme that releases NO) increased, as demonstrated by the experimental results. Therefore the significance of PDT in enhancing the clinical condition of the lesion is thus highlighted., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

45. Editorial: Implications of the inflammatory role of skin dendritic cells for health, disease and forensic practice.

Author: Fernandez Guarino M and Bacci S
Abstract: Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Published: 2024
Full Text: View/download PDF

46. Unlocking the Power of Light on the Skin: A Comprehensive Review on Photobiomodulation.

Author: Hernández-Bule ML, Naharro-Rodríguez J, Bacci S, and Fernández-Guarino M
Subjects: Humans, Animals, Skin Diseases radiotherapy, Skin Diseases therapy, Light, Phototherapy methods, Low-Level Light Therapy methods, Skin radiation effects, Skin metabolism
Abstract: Photobiomodulation (PBM) is a procedure that uses light to modulate cellular functions and biological processes. Over the past decades, PBM has gained considerable attention for its potential in various medical applications due to its non-invasive nature and minimal side effects. We conducted a narrative review including articles about photobiomodulation, LED light therapy or low-level laser therapy and their applications on dermatology published over the last 6 years, encompassing research studies, clinical trials, and technological developments. This review highlights the mechanisms of action underlying PBM, including the interaction with cellular chromophores and the activation of intracellular signaling pathways. The evidence from clinical trials and experimental studies to evaluate the efficacy of PBM in clinical practice is summarized with a special emphasis on dermatology. Furthermore, advancements in PBM technology, such as novel light sources and treatment protocols, are discussed in the context of optimizing therapeutic outcomes and improving patient care. This narrative review underscores the promising role of PBM as a non-invasive therapeutic approach with broad clinical applicability. Despite the need for further research to develop standard protocols, PBM holds great potential for addressing a wide range of medical conditions and enhancing patient outcomes in modern healthcare practice.
Published: 2024
Full Text: View/download PDF

47. Conditioning on the Pre-Test versus Gain Score Modelling: Revisiting the Controversy in a Multilevel Setting.

Author: Arpino B, Bacci S, Grilli L, Guetto R, and Rampichini C
Abstract: We consider estimating the effect of a treatment on a given outcome measured on subjects tested both before and after treatment assignment in observational studies. A vast literature compares the competing approaches of modelling the post-test score conditionally on the pre-test score versus modelling the difference, namely, the gain score. Our contribution lies in analyzing the merits and drawbacks of two approaches in a multilevel setting. This is relevant in many fields, such as education, where students are nested within schools. The multilevel structure raises peculiar issues related to contextual effects and the distinction between individual-level and cluster-level treatments. We compare the two approaches through a simulation study. For individual-level treatments, our findings align with existing literature. However, for cluster-level treatments, the scenario is more complex, as the cluster mean of the pre-test score plays a key role. Its reliability crucially depends on the cluster size, leading to potentially unsatisfactory estimators with small clusters., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Published: 2024
Full Text: View/download PDF

48. Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019.

Author: Merdrignac L, Aït El Belghiti F, Pandolfi E, Acosta L, Fabiánová K, Habington A, García Cenoz M, Bøås H, Toubiana J, Tozzi AE, Jordan I, Zavadilová J, O'Sullivan N, Navascués A, Flem E, Croci I, Jané M, Křížová P, Cotter S, Fernandino L, Bekkevold T, Muñoz-Almagro C, Bacci S, Kramarz P, Kissling E, and Savulescu C
Subjects: Infant, Female, Humans, Sentinel Surveillance, Case-Control Studies, Pertussis Vaccine, Vaccination methods, Hospitalization, Whooping Cough epidemiology, Whooping Cough prevention & control
Abstract: Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year., Methods: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it)., Results: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose., Conclusions: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three., Competing Interests: Declaration of competing interest No conflict of interest to declare except for Elmira Flem who has been employed since April 2019 by Merck & Co., Inc., North Wales, PA, USA. The work for the current study was conducted by Dr. Flem under the previous affiliation at the Norwegian Institute of Public Health., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

49. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.

Author: Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Kristoffersen AB, Machado A, Soares P, Nardone A, Bacci S, Kissling E, and Nunes B
Subjects: Humans, Aged, Male, Aged, 80 and over, Female, Retrospective Studies, Vaccination statistics & numerical data, Europe epidemiology, Electronic Health Records, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, European Union, Hospitalization statistics & numerical data, SARS-CoV-2 immunology, Vaccine Efficacy
Abstract: Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

50. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.

Author: Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, Enouf V, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, and Kissling E
Subjects: Humans, Adolescent, Aged, COVID-19 Vaccines, SARS-CoV-2, BNT162 Vaccine, Vaccine Efficacy, Europe epidemiology, Primary Health Care, COVID-19 epidemiology, COVID-19 prevention & control, Influenza, Human epidemiology, Influenza, Human prevention & control
Abstract: BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases.MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection.ResultsAmong adults, PS VE was 37% (95% CI: 24-47%) overall and 60% (95% CI: 44-72%), 43% (95% CI: 26-55%) and 29% (95% CI: 13-43%) < 90, 90-179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32-51%) overall and 56% (95% CI: 47-64%), 22% (95% CI: 2-38%) and 3% (95% CI: -78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification.ConclusionPrimary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

126 results on '"Bacci, S"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources